Methods and compositions for improving athletic performance
Through the use of urdenafil, the exercise performance and heart function of patients with single ventricular heart disease has been improved, and the problem of decreased exercise ability and heart function in patients with Fontan circulation has been solved, thereby improving myocardial performance and delaying the disease.
Patent Information
- Application Number
- CN202280092060.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-12-20
- Filing Date
- 2022-12-20
- Publication Date
- 2024-12-03
AI Technical Summary
Patients with single ventricular heart disease (SVHD), especially those with Fontan circulation, have decreased exercise performance and cardiac function, and lack effective drug therapies to improve myocardial performance, exercise capacity and lifespan.
Improve the exercise performance and cardiac function of SVHD patients by daily administration of effective doses, including improving myocardial performance index (MPI), exercise capacity at maximum VO2, ventilation anaerobic threshold, using urdenafil or a pharmaceutically acceptable salt, including improving the myocardial performance index (MPI), and exercise capacity at maximum VO2, and ventilation anaerobic threshold. Exercise ability and power, VE/VCO2, diastolic pressure and oxygen saturation at rest.
It significantly improves the systolic and diastolic function of the single-function normal ventricle, increases cardiac output, delays the decline of exercise capacity, reduces venous pressure, improves oxygen saturation and exercise performance, and reduces the risk of complications.
Smart Images

Figure CN119072312A_ABST
Abstract
Description
[0001] Government Rights Statement
[0002] This work was funded, at least in part, by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. Major funding support was given to New England Research Institutes, Inc. through NHLBI grants U24 HL135691 and / or U01 HL068270. Funding was given to the Pediatric Heart Network Clinical Site (UG1 HL135685, UG1HL135680, UG1HL135683, UG1 HL135689, UG1 HL135682, UG1 HL135665, UG1 HL135646, UG1HL135678, UG1 HL135666). The government may have certain rights in the data and inventions disclosed herein.
[0003] Related Applications
[0004] This provisional application claims priority to provisional application serial number 63 / 291,858 filed on December 20, 2021. Related provisional applications include provisional application serial number 62 / 905,350 filed on September 24, 2019, provisional application serial number 62 / 936,497 filed on November 16, 2019, and provisional application serial number 63 / 023,070 filed on May 11, 2020. Technical Field
[0005] Methods for improving exercise performance in patients with univentricular heart disease ("SVHD"), including SVHD patients with Fontan physiology ("Fontan patients"), particularly improving exercise performance at peak or maximum VO2 in a sub-super Fontan population (i.e., a subgroup of Fontan patients whose baseline peak or maximum VO2 is less than (<) 80% of the predicted value), and improving exercise performance at the ventilatory anaerobic threshold ("VAT") in both a super Fontan population (i.e., Fontan patients whose baseline peak or maximum VO2 is greater than or equal to (≥) 80% of the predicted value) and a sub-super Fontan population. Background Art
[0006] The heart is a muscular organ that pumps blood through the blood vessels of the circulatory system. In humans, the heart is located between the lungs and the chest and is divided into a left and right side. A normal human heart has four chambers, the left atrium and left ventricle on the left, and the right atrium and right ventricle on the right. Oxygen-poor blood ("blue blood") enters the right side through the right atrium, and fresh oxygenated blood ("red blood") leaves the left side through the left ventricle. The heart has four valves, the tricuspid valve, the pulmonary valve, the mitral valve, and the aortic valve. These valves prevent blood from flowing back inside the heart and force blood to flow in a forward direction to the lungs and body.
[0007] The human heart beats (expands and contracts) about 100,000 times a day, pumping 5 to 6 quarts of blood per minute, or about 2,000 gallons per day. The left ventricle, the main pumping chamber of the heart, pumps freshly oxygenated blood (red blood) to the body through the aortic valve. The blood then circulates through the arteries and arterioles to all parts of the body, delivering oxygen and nutrients. As the blood travels through the circulation, it exchanges oxygen and nutrients for carbon dioxide and metabolic waste products. During this process, the blood changes from oxygen-rich blood (red blood) to oxygen-poor blood (blue blood). The oxygen-poor blood then returns to the right atrium through the body's veins. The blue blood passes from the right atrium to the right ventricle through the tricuspid valve, and is then pumped by the right ventricle to the lungs, exchanging carbon dioxide for oxygen. The now freshly oxygenated blood (red blood) returns from the lungs to the left atrium via the pulmonary veins. The blood passes from the left atrium to the left ventricle through the mitral valve, and is then pumped to the body to begin the cycle again.
[0008] Therefore, the normal human cardiovascular system consists of the pulmonary circulation and the systemic circulation, which are connected in series and powered by the pumping of the left and right ventricles.
[0009] Gewillig M.: Congenital heart disease. THE FONTAN CIRCULATION. Heart, 91: 839-846 (2005).
[0010] Univentricular Heart Disease (SVHD) is a rare pediatric condition that includes a group of heart malformations, each of which results in the presence of only a single functional ventricle (pumping chamber). In other words, unlike newborns who have normal hearts (four chambers and two ventricles), newborns with SVHD are born with only one functioning ventricle (one pumping chamber), i.e. a univentricular heart. The non-functioning or missing ventricle (pumping chamber) may be smaller than a single ventricle and therefore unable to function adequately, it may also be completely absent, or it may be configured to prevent it from facilitating the normal flow of blood through the circulation. Examples of SVHD include hypoplastic left heart syndrome, tricuspid atresia, double inlet left ventricle, etc.
[0011] Typically, newborns with SVHD appear cyanotic, which is blue in color, because a mixture of oxygen-poor blood (blue blood) and oxygen-rich blood (red blood) mix together in the single ventricle. The amount of oxygen in the blood mixture that leaves the heart is closely related to the type, severity, and location of the SVHD heart defect. Some newborns with SVHD will have mild cyanosis, while others will have severe cyanosis and require early intervention to meet the oxygen the body needs to survive. Unfortunately, without surgical intervention, most newborns born with SVHD do not survive.
[0012] SVHD can be considered to have two main subtypes. In the first subtype, the left ventricle and aorta (the main artery to the body) are underdeveloped, and the heart cannot pump blood to the body without intervention. In the second subtype, the right ventricle and pulmonary artery (the main artery to the lungs) are underdeveloped, and the heart cannot pump blood to the lungs.
[0013] For those infants born with an underdeveloped left ventricle and aorta (subtype 1), urgent intervention is needed within the first few days or weeks of life to stabilize blood flow to the body. This intervention is called the Norwood procedure (see Figure 5 ), involves the reconstruction of the aorta (the main artery to the body) using the pulmonary valve and pulmonary artery along with patch material. Since the Norwood procedure repurposes the pulmonary artery to supply blood to the body, a route for blood to reach the lungs must also be included. This is accomplished by including a "shunt" of blood from the aortic circulation to the pulmonary circulation. This shunt is usually a tube graft placed between the right subclavian artery (the artery that supplies blood to the right arm) and the right pulmonary artery. The Norwood procedure allows newborns to survive past infancy, but is not a permanent solution. This temporary surgery forces the heart's single pumping chamber to pump blood to both the body and the lungs, placing it under pressure. To relieve this pressure, two other surgeries are needed. The first of these two is the Glenn shunt or semi-Fontan (see Figure 6 ), which is performed at 4-6 months and involves connecting the superior vena cava (the main vein in the upper body) directly to the pulmonary artery. This allows blue blood from the upper body to return to the lungs for oxygenation without the need for a ventricular pump. The final surgery is the Fontan procedure, see Figure 1A and Figure 7, which is usually performed at 18-48 months of age and involves connecting the inferior vena cava (the main vein in the lower body) directly to the pulmonary artery. This allows the blue blood in the lower body to return to the lungs for oxygenation without the need for a specialized ventricular pump to pump blood to the lungs. After the Fontan procedure, all blue blood returns to the lungs and all red blood returns from the lungs to the heart, but this is done without the help of a specialized ventricular pump to pump blood through the lungs to the heart, as in a normal four-chambered heart.
[0014] For those infants born with a hypoplastic right ventricle and pulmonary artery (the second subtype), emergency neonatal intervention is usually not needed. This group of infants requires close monitoring to determine if there is too little blood flow to the lungs, too much blood flow to the lungs, or the right amount of blood flow to allow for growth and development. If there is too little blood flow to the lungs, a shunt is usually placed, similar to how part of the Norwood procedure is done. If there is too much blood flow to the lungs, a restrictor may be placed around the pulmonary artery to reduce the amount of blood flow to the lungs to avoid congestive heart failure. If there is an appropriate amount of blood flow to the lungs, infants born with a hypoplastic right ventricle and pulmonary artery may get through the first few months of their lives without the need for surgical intervention. Regardless of whether there is too little, too much, or the right amount of blood flow to the lungs, infants with this type of SVHD still need a Glenn shunt or a semi-Fontan at 4-6 months of age and a Fontan at 18-48 months of age to relieve the heart and separate the blue blood from the red blood.
[0015] After the Fontan procedure, the subtype of univentricular heart disease is less important, as all patients share a common physiology: (i) passive blood flow from the superior and inferior vena cava bypassing the heart directly to the lungs and (ii) a single ventricle that pumps blood to the body. Although this "Fontan circulation" has kept thousands of patients alive for the past 40-50 years, it is far from normal. Without a ventricular pump to push blood back through the lungs to the heart, the Fontan circulation must rely on the pressure generated by the veins in the body to accomplish this task. This results in very high "blood pressure" within the veins and also limits the amount of flow that can circulate through the body in a given amount of time - this is known as reduced cardiac output.
[0016] Over time, the combination of increased intravenous pressure and reduced cardiac output leads to a predictable series of long-term complications that ultimately result in a greatly reduced duration of survival. Complications associated with Fontan circulation include: kidney and liver damage, overload of the lymphatic circulation leading to protein loss in the lungs or gastrointestinal tract, bleeding and coagulation disorders (including risk of stroke), and progressive dysfunction of the heart's own pumping ability.
[0017] The ability to perform exercise is used as a marker of circulatory health in many forms of heart disease. For patients with Fontan circulation, exercise is equally an important measure of health and a good predictor of outcome. While exercise capacity is often maintained during childhood in patients with Fontan circulation, it typically begins to decline during adolescence and early adulthood. This deterioration is associated with an increase in the prevalence of heart failure symptoms, hospitalizations, and mortality, often due to complications of the Fontan circulation itself. In some cases, heart transplantation may still be a treatment option, but heart transplantation comes with its own set of risks, and patients with Fontan circulation may be poor candidates for heart transplantation due to long-term and progressive dysfunction of many organ systems.
[0018] Despite this being a long-standing and very serious congenital heart disease, to date, no drug therapy has been approved by the U.S. Food and Drug Administration (FDA) or any other equivalent agency worldwide for the treatment of patients with SVHD, including Fontan patients. Therefore, patients with SVHD, including Fontan patients, do need and demand new drug therapies that are associated with complications of SVHD and Fontan circulation, with the goal of extending the lifespan of patients with SVHD, including Fontan patients, and avoiding or delaying disease progression and the need for heart transplantation.
[0019] There is also a real need and demand for new pharmacological therapies for SVHD patients (including Fontan patients) to (i) improve myocardial performance index ("MPI"), (ii) improve single ventricle performance, (iii) improve exercise capacity at ventilatory anaerobic threshold (VAT) and / or maximal aerobic capacity (VO2max or VO2max), (iv) improve work rate at VAT, (v) improve ventilatory equivalent of carbon dioxide (VE / VCO2) at VAT, and / or (vi) improve single ventricle cardiac performance. Summary of the invention
[0020] The present invention overcomes the above-mentioned shortcomings and drawbacks associated with current treatments for SVHD patients, including Fontan patients, by discovering novel methods for treating SVHD patients, including Fontan patients.
[0021] Generally speaking, the methods of the present invention involve the use of udenafil or a pharmaceutically acceptable salt thereof to treat SVHD patients (including Fontan patients).
[0022] More specifically, the method of the present invention comprises administering an effective amount of Udenafil or a pharmaceutically acceptable salt thereof to SVHD patients (including Fontan patients), preferably daily, to improve their MPI and exercise capacity or performance, etc.
[0023] Generally speaking, the methods of the present invention comprise administering to SVHD patients (including Fontan patients) daily an effective amount of Udenafil or a pharmaceutically acceptable salt thereof to improve the following motor performance:
[0024] (a) Ventricular performance of a single functional normal ventricle in patients with SVHD as measured by MPI;
[0025] (b) Exercise capacity as measured by oxygen consumption under VAT;
[0026] (c) Exercise capacity as measured by oxygen consumption at maximal effort or VO2max;
[0027] (d) Power consumption under VAT;
[0028] (e) VE / VCO2 under VAT;
[0029] (f) diastolic blood pressure at rest; and
[0030] (g) Oxygen saturation at rest (%), each individually, collectively or in any combination.
[0031] Preferably, the method of the present invention improves (a)-(g) listed above, including individually, collectively or in any combination thereof. Preferably, the method of the present invention improves at least the combination of (a)-(e) listed above. Most preferably, according to the present invention, (a)-(g) listed above are improved by administering an effective amount of Udenafil or a pharmaceutically acceptable salt thereof to SVHD patients (including Fontan patients) daily, including individually, collectively or in any combination thereof.
[0032] According to the methods of the present invention, improvements in single ventricular performance include improvements in systolic and diastolic function. These can be demonstrated by, but are not limited to, improvements in blood pool MPI, tissue Doppler MPI, cardiac output (estimated by the product of the integral under the Doppler-derived outflow curve and heart rate), and other measures of single ventricular cardiac performance. According to the methods of the present invention, improvements in exercise capacity or performance include, but are not limited to, improvements in exercise capacity or performance at the anaerobic threshold ("VAT") and / or improvements in exercise capacity or performance at maximum effort or maximum VO2. Also according to the present invention, when practicing the methods of the present invention on SVHD patients (including Fontan patients), work done at VAT, ventilation equivalent of carbon dioxide at VAT (VE / VCO2), diastolic pressure at rest, and / or oxygen saturation (%) at rest are improved.
[0033] Generally, "effective amount" as used herein refers to an amount of Udenafil or a pharmaceutically acceptable salt thereof that is sufficient to cause or induce a therapeutic or pharmacological effect without causing treatment-limiting side effects.
[0034] More specifically, "effective amount" as used herein refers to an amount of Udenafil or a pharmaceutically acceptable salt thereof that is sufficient to cause or induce a therapeutic or pharmacological effect in SVHD patients (including Fontan patients) without causing treatment-limiting toxicity, treatment-limiting side effects associated with the inhibition of PDE6 and / or PDE11, and / or any other treatment-limiting side effects.
[0035] According to the present invention, examples of an "effective amount" of Udenafil or a pharmaceutically acceptable salt thereof include a daily total amount, ranging from but not limited to about 87.5 mg to about 175 mg. More preferably, according to the present invention, an "effective amount" of Udenafil or a pharmaceutically acceptable salt thereof includes a daily total amount in the range of about 125 mg to about 175 mg. Even more preferably, according to the present invention, an "effective amount" of Udenafil or a pharmaceutically acceptable salt thereof includes an oral dose, which includes but is not limited to a single dose administered daily, including a single dose of about 75 mg or 87.5 mg administered once or twice a day, and a single dose of about 125 mg administered once a day.
[0036] The present invention also contemplates a method comprising administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof, preferably daily, to SVHD patients (including Fontan patients) to improve, MPI, ventricular performance, cardiac output, exercise capacity or performance at VAT, exercise capacity or performance at maximal effort or VO2max, work capacity at VAT, VE / VCO2 at VAT, diastolic blood pressure at rest, and oxygen saturation (%) at rest, etc., individually, collectively, or in any combination, without causing treatment-limiting side effects, such as interference with visual conduction or function, back pain, myalgia, sperm concentration or quality. In other words, the present invention contemplates the treatment, preferably daily treatment, of SVHD patients (including Fontan patients) using an effective amount of an effective PDE5 inhibitor, preferably udenafil or a pharmaceutically acceptable salt thereof, without causing treatment-limiting side effects associated with the inhibition of phosphodiesterase-6 ("PDE6") and / or phosphodiesterase-11 ("PDE11"). As used herein, PDE6 includes any isozyme, variant, catalytic subunit and / or inhibitory subunit of PDE6, such as PDE6a, PDE6P, PDE6Y, PDE6R and / or PDE6C, individually, collectively or in any combination. As used herein, PDE11 includes any isozyme, variant, catalytic subunit and / or inhibitory subunit of phosphodiesterase-11A (PDEIIA) and PDE11, such as PDE11A, including PDE11A1, PDE11A2, PDE11A3 and / or PDE11A4, individually, collectively or in any combination.
[0037] In one embodiment, the present invention relates to a method for improving MPI in SVHD patients (including Fontan patients). As used herein, MPI measures systolic and diastolic function and is used to assess overall cardiac function. The method comprises administering to the patient, preferably daily, an effective amount of an effective PDE5 inhibitor, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0038] It should be understood that "improve, improve, improvement in, or improved," in the context of MPI according to the present invention, refers herein to improving single ventricle performance, i.e., improving the diastolic and systolic function of a single functioning normal ventricle. In other words, a single functioning normal ventricle squeezes better or more efficiently with each heartbeat. As a result, the cardiac output and the amount of blood that can circulate throughout the body in a given time are increased or improved in SVDD patients (including Fontan patients) who practice or are treated according to the methods of the present invention, particularly compared to SVHD patients (including Fontan patients) who are not treated according to the methods of the present invention. Therefore, the methods of the present invention can result in an improvement in the MPI or other published measures of single ventricle performance in SVHD patients (including Fontan patients) compared to the MPI or other published measures of single ventricle performance in the absence of the methods of the present invention (such as in the absence of the administration of Udenafil). For example, the improvement can be about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, or about 30% or more improvement compared to the blood pool MPI or other published measure of single ventricle performance in the absence of the methods of the present invention (such as in the absence of daily udenafil administration).
[0039] The method comprises administering to the patient an effective amount of an effective PDE5 inhibitor, preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0040] In one embodiment, the present invention relates to a method for improving the systolic function of a single functional normal ventricle in a SVHD patient (including a Fontan patient). The method comprises administering to the SVHD patient an effective amount of an effective PDE5 inhibitor or a pharmaceutically acceptable salt thereof, preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0041] In one embodiment, the present invention relates to a method for improving diastolic function of a single functioning normal ventricle in a SVHD patient (including a Fontan patient). The method comprises administering to the SVHD patient an effective amount of an effective PDE5 inhibitor or a pharmaceutically acceptable salt thereof, preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0042] In one embodiment, the present invention relates to a method for improving cardiac output of a single functioning normal ventricle in a SVHD patient (including a Fontan patient). The method comprises administering to the SVHD patient an effective amount of an effective PDE5 inhibitor or a pharmaceutically acceptable salt thereof, preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0043] In one embodiment, the present invention relates to a method for improving the compressive capacity of a single functioning normal ventricle in a SVHD patient (including a Fontan patient). The method comprises administering to a SVHD patient (including a Fontan patient) an effective amount of an effective PDE5 inhibitor or a pharmaceutically acceptable salt thereof, preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0044] In another embodiment, the present invention relates to a method of improving venous pressure by reducing elevated venous pressure in SVHD patients (including Fontan patients). The method comprises administering to SVHD patients (including Fontan patients) an effective amount of an effective PDE5 inhibitor, preferably daily, wherein the PDE5 inhibitor is preferably Udenafil or a pharmaceutically acceptable salt thereof.
[0045] In one embodiment, the present invention relates to a method of improving the amount of blood that can circulate through the body of a SVHD patient (including Fontan patients) in a given amount of time. The method comprises administering to the SVHD patient (including Fontan patients) an effective amount of an effective PDE5 inhibitor or a pharmaceutically acceptable salt thereof, preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0046] Therefore, the present invention relates to a method for improving the overall single ventricular performance of a single functioning normal ventricle in SVHD patients (including Fontan patients). The method comprises administering to the SVHD patient an effective amount of an effective PDE5 inhibitor or a pharmaceutically acceptable salt thereof, preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0047] In yet another embodiment, the present invention relates to a method for improving resting diastolic blood pressure in SVHD patients (including Fontan patients), such that resting diastolic blood pressure in SVHD patients (including Fontan patients) is significantly reduced. The method comprises administering to SVHD patients (including Fontan patients) an effective amount of an effective PDE5 inhibitor, preferably daily, wherein the PDE5 inhibitor is preferably Udenafil or a pharmaceutically acceptable salt thereof.
[0048] In yet another embodiment, the present invention relates to a method for improving resting oxygen saturation (%) in SVHD patients (including Fontan patients). The method comprises administering to SVHD patients (including Fontan patients) an effective amount of an effective PDE5 inhibitor, preferably daily, wherein the PDE5 inhibitor is preferably Udenafil or a pharmaceutically acceptable salt thereof.
[0049] In yet another embodiment, the present invention relates to a method for improving motor performance or motor ability in SVHD patients (including Fontan patients). The method comprises administering to SVHD patients (including Fontan patients) an effective amount of an effective PDE5 inhibitor, preferably daily, wherein the PDE5 inhibitor is preferably Udenafil or a pharmaceutically acceptable salt thereof.
[0050] In another embodiment, the present invention relates to a method of improving exercise performance or capacity at the ventilatory anaerobic threshold ("VAT") in SVHD patients (including Fontan patients). The method of the present invention results in improved VO2 under VAT in SVHD patients (including Fontan patients) compared to VO2 under VAT in SVHD patients (including Fontan patients) not treated with the method of the present invention or not practicing the method of the present invention (e.g., in the absence of daily udenafil administration according to the method of the present invention). For example, the improvement can be about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, or about 30% or more improvement compared to VO2 under VAT in the absence of the methods of the present invention (e.g., in the absence of daily udenafil administration). The method comprises administering an effective amount of an effective PDE5 inhibitor to a SVHD patient (including a Fontan patient), preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0051] In another embodiment, the invention relates to a method of improving exercise performance or capacity at maximal effort or VO2max in SVHD patients (including Fontan patients). The method of the invention results in improved VO2 at maximal effort in SVHD patients (including Fontan patients) compared to VO2 at maximal effort in the absence of the method of the invention (e.g., in the absence of daily udenafil administration). For example, the improvement can be about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, or about 30% or more compared to VO2 at maximal effort in the absence of the methods of the present invention (e.g., in the absence of daily udenafil administration). The method comprises administering an effective amount of an effective PDE5 inhibitor to a SVHD patient (including a Fontan patient), preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0052] In another embodiment, the present invention relates to a method for improving the efficiency of operation under VAT in SVHD patients (including Fontan patients). Compared with the efficiency of operation under VAT in the absence of the method of the present invention (e.g., in the absence of daily udenafil administration), the method of the present invention results in improved efficiency of operation under VAT in SVHD patients (including Fontan patients). For example, the improvement can be about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29% or about 30% or more compared to the efficiency of operation under VAT in the absence of the method of the present invention (e.g., in the absence of daily udenafil administration). The method comprises administering to a SVHD patient (including a Fontan patient) an effective amount of an effective PDE5 inhibitor, preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0053] In another embodiment, the invention relates to a method of improving the ventilatory equivalent of carbon dioxide at VAT ("VE / VCO2") at VAT in SVHD patients (including Fontan patients). The method of the invention results in improved VE / VCO2 at VAT in SVHD patients (including Fontan patients) compared to VE / VCO2 at VAT in the absence of the method of the invention (e.g., in the absence of daily udenafil administration). For example, the improvement can be about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, or about 30% or more compared to VO2 under VAT in the absence of the methods of the present invention (e.g., in the absence of daily udenafil administration). The method comprises administering an effective amount of an effective PDE5 inhibitor to a SVHD patient (including a Fontan patient), preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0054] In one embodiment, the present invention is directed to improved methods for treating SVHD patients, including Fontan patients, undergoing cardiac reconstruction of an abnormal SVHD heart, wherein the daily methods of the present invention result in fewer or milder adverse events compared to conventional methods of treating such SVHD patients, including Fontan patients.
[0055] In another embodiment, the method of the present invention results in few, if any, serious adverse events, moderate adverse events, or mild adverse events. The method comprises administering to a SVHD patient (including a Fontan patient) an effective amount of an effective PDE5 inhibitor, preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0056] In one embodiment, the invention relates to improved methods for treating SVHD patients who have undergone the Fontan procedure. In one such embodiment, the Fontan patient was diagnosed with Hypoplastic Left Heart Syndrome (HLHS) but first underwent the Norwood procedure, see, e.g. Figure 5 , followed by a semi-Fontan or bidirectional Glenn procedure, see e.g. Figure 6 , followed by Fontan surgery, see, e.g. Figure 1A and Figure 7In another such embodiment, the Fontan patient first undergoes a semi-Fontan or bidirectional Glenn procedure before undergoing the Fontan procedure. The method comprises administering to the SVHD patient (including the Fontan patient) an effective amount of an effective PDE5 inhibitor, preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0057] In one embodiment, the present invention relates to an improved method for treating SVHD patients (including Fontan patients), wherein SVHD is selected from the group consisting of atrioventricular canal defect (AV Canal), double inlet left ventricle (DILV), double outlet right ventricle (DORV), Ebstein anomaly, HLHS, mitral atresia (usually associated with HLHS), pulmonary atresia with intact ventricular septum (PA / IVS), single left ventricle, tricuspid atresia, and tricuspid atresia with stenosis. The method comprises administering to SVHD patients (including Fontan patients) an effective amount of an effective PDE5 inhibitor, preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the method of the present invention comprises administering to SVHD patients (including Fontan patients) once a day an effective amount of an effective PDE5 inhibitor or a pharmaceutically acceptable salt thereof, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0058] In another embodiment, the method of the present invention comprises administering an effective amount of an effective PDE5 inhibitor or a pharmaceutically acceptable salt thereof to SVHD patients (including Fontan patients) twice daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0059] In another embodiment, the method of the present invention comprises administering an effective amount of an effective PDE5 inhibitor or a pharmaceutically acceptable salt thereof to SVHD patients (including Fontan patients) three or more times a day, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof.
[0060] In another embodiment, the SVHD patient (including Fontan patients) is a pediatric patient between about 2 and about 18 years of age. The methods of the present invention also encompass the treatment of adult patients.
[0061] In yet another embodiment, the present invention is directed to improved methods for treating SVHD patients (including Fontan patients), wherein the methods of the present invention show improved compliance of SVHD patients (including Fontan patients) with a dosing schedule of Udenafil or a pharmaceutically acceptable salt thereof, compared to SVHD patients (including Fontan patients) who prescribe non-Udenafil medications.
[0062] Finally, in yet another embodiment, the methods of the present invention may result in a unique pharmacokinetic profile. The pharmacokinetic profile may include a C between 300 and 700 ng / ml. max , or more specifically, about 500 ng / ml; a T between 1 and 1.6 hours max , or more specifically, about 1.3 hours; AUT between 2550 and 4150 ng·hr / ml or more t , specifically, about 3350 ng·hr / ml; and an AUC between 5110 and 8290 ng·hr / ml or more 0-24 , specifically, about 6701ng·hr / ml.
[0063] It should be understood that the present invention contemplates such Udenafil drug products that are therapeutically equivalent to the Udenafil drug products of the present invention. In other words, the present invention contemplates such Udenafil drug products that are (i) therapeutically equivalent, (ii) bioequivalent, (iii) interchangeable, and (iv) bioavailable, and are effective in achieving or performing the purposes of the present invention when administered to SVHD patients (including Fontan patients) according to the methods of the present invention.
[0064] Thus, in one embodiment according to the invention, the invention contemplates a pharmaceutical formulation having a 90% confidence interval (90% CI) for a pharmacokinetic profile wherein the ratio of means is within a range between about 0.8 and about 1.25. In another embodiment according to the invention, the invention contemplates interchangeable udenafil pharmaceutical formulations having a 90% confidence interval (90% CI) for a pharmacokinetic profile wherein the ratio of means is within a range between about 0.8 and about 1.2. Thus, the invention contemplates SVHD patients (including Fontan patients) treated with or practicing the methods of the invention having plasma concentrations of udenafil that result in a pharmacokinetic profile (such as its C max , T max More preferably, the present invention contemplates SVHD patients (including Fontan patients) treated or practicing the methods of the present invention who have plasma concentrations of udenafil that result in a pharmacokinetic profile (e.g., C max , T max , AUC t and AUC 0-24 ) varies up to about 40% (i.e., -20 to +20%). For example, the present invention contemplates that SVHD patients (including Fontan patients) treated with or practicing the methods of the present invention have the following pharmacokinetic profile of Udenafil:
[0065] (a) about -20% to about +25% C at about 500 ng / ml max Plasma concentrations, and more preferably, about 500 ng / ml of about -20% to about +20% of Udenafil C max Plasma concentration;
[0066] (b) T of about -20% to about +25% for about 1.3 hours max , and more preferably, about -20% to about +20% of Udenafil T for about 1.3 hours max ;
[0067] (c) AUC of about -20% to about +25% of about 3350 ng·hr / ml t , and more preferably, about -20% to about +20% of the Udenafil AUC of about 3350 ng·hr / ml t ;as well as
[0068] (d) AUC of about -20% to about +25% of about 6701 ng·hr / ml 0-24 , and more preferably, about -20% to about +20% of the Udenafil AUC of about 6701 ng·hr / ml 0-24 , individually, jointly or in any combination.
[0069] Therefore, the present invention contemplates bioequivalent and interchangeable Udenafil drug products for use in the methods according to the present invention. In addition, the present invention contemplates the production of the above-mentioned C in SVHD patients (including Fontan patients) when administered to SVHD patients (including Fontan patients) according to the methods of the present invention. max , T max , AUC t and / or AUC 0-24 Udenafil drug product.
[0070] The methods of the present invention include but are not limited to:
[0071] 1. A method of treating a patient with univentricular heart disease (SVHD) having a single functioning normally functioning ventricle and Fontan physiology after a Fontan procedure (a Fontan patient) and in need of treatment to improve said Fontan patient's exercise capacity as measured by oxygen consumption at maximal effort or peak VO2, wherein said Fontan patient has a baseline peak or maximum VO2 that is less than (<) 80% of predicted, and wherein said Fontan patient's exercise capacity is adversely affected due to a decrease in cardiac function in said Fontan patient after said Fontan procedure, said method comprising:
[0072] An effective amount of Udenafil or a pharmaceutically acceptable salt thereof is administered daily to the Fontan patient to improve the Fontan patient's exercise capacity as measured by oxygen consumption under maximum effort or peak VO2.
[0073] 2. The method of claim 1, wherein the effective amount is a total daily dose of Udenafil or a pharmaceutically acceptable salt thereof in an amount between about 125 mg and 175 mg.
[0074] 3. The method of claim 1, wherein the effective daily amount is a total daily dose of Udenafil or a pharmaceutically acceptable salt thereof in an amount of about 175 mg.
[0075] 4. The method of claim 3, wherein the total daily dose consists of two separate doses of Udenafil or a pharmaceutically acceptable salt thereof, wherein each of the separate doses is about 87 mg of Udenafil or a pharmaceutically acceptable salt thereof.
[0076] 5. The method of claim 4, wherein each of said individual doses is a solid oral dosage form.
[0077] 6. The method according to claim 5, wherein the Udenafil or a pharmaceutically acceptable salt thereof is a solid or semisolid oral dosage form selected from tablets, capsules, gels, liquids, liquid dispersions, pills, powders and suspensions.
[0078] 7. The method of claim 1, wherein the Udenafil or a pharmaceutically acceptable salt thereof is a solid oral dosage form.
[0079] 8. The method of claim 7, wherein the solid oral dosage form is a solid or semisolid oral dosage form selected from the group consisting of tablets, capsules, gels, liquids, liquid dispersions, pills, powders, and suspensions.
[0080] 9. The method of claim 1, wherein the Fontan patient is at least 12 years old.
[0081] 10. The method of claim 1, wherein the method further improves the following motor performance of the Fontan patient:
[0082] (a) ventricular performance of a single normally functioning ventricle in a Fontan patient as measured by the myocardial performance index (MPI);
[0083] (b) exercise capacity measured by oxygen consumption at the ventilatory anaerobic threshold (VAT);
[0084] (c) performance under VAT; and
[0085] (d) VE / VCO2 under VAT, either alone or in any combination.
[0086] 11. A method of treating a patient with univentricular heart disease (SVHD) having a single functioning normal ventricle and Fontan physiology following a Fontan procedure (a super Fontan patient) and in need of treatment to improve said super Fontan patient's exercise capacity as measured by oxygen consumption at maximal effort or peak VO2, wherein said super Fontan patient has a baseline peak or maximum VO2 greater than or equal to (≥) 80% predicted, and wherein said super Fontan patient's exercise capacity is adversely affected due to a decrease in cardiac function in said super Fontan patient following said Fontan procedure, said method comprising:
[0087] An effective amount of Udenafil or a pharmaceutically acceptable salt thereof is administered daily to the super-Fontan patient to improve the exercise capacity of the super-Fontan patient as measured by oxygen consumption at the ventilatory anaerobic threshold (VAT).
[0088] 12. The method of claim 11, wherein the effective amount is a total daily dose of Udenafil or a pharmaceutically acceptable salt thereof in an amount between about 125 mg and 175 mg.
[0089] 13. The method of claim 11, wherein the effective amount is a total daily dose of Udenafil or a pharmaceutically acceptable salt thereof in an amount of about 175 mg.
[0090] 14. The method of claim 13, wherein the total daily dose consists of two separate doses of Udenafil or a pharmaceutically acceptable salt thereof, wherein each of the separate doses is about 87 mg of Udenafil or a pharmaceutically acceptable salt thereof.
[0091] 15. The method of claim 14, wherein each of said individual doses is a solid oral dosage form.
[0092] 16. The method of claim 15, wherein the Udenafil or a pharmaceutically acceptable salt thereof is a solid or semisolid oral dosage form selected from tablets, capsules, gels, liquids, liquid dispersions, pills, powders and suspensions.
[0093] 17. The method of claim 11, wherein the Udenafil or a pharmaceutically acceptable salt thereof is a solid oral dosage form.
[0094] 18. The method of claim 17, wherein the solid oral dosage form is a solid or semisolid oral dosage form selected from the group consisting of tablets, capsules, gels, liquids, liquid dispersions, pills, powders, and suspensions.
[0095] 19. The method of claim 11, wherein the Super Fontan patient is at least 12 years old.
[0096] 20. The method of claim 11, wherein the method further improves the following motor performance of the Super Fontan patient:
[0097] (a) ventricular performance of a single functional normal ventricle of said Super Fontan patient as measured by the Myocardial Performance Index (MPI);
[0098] (b) performance under VAT; and
[0099] (d) VE / VCO2 under VAT, either individually or in any combination.
[0100] It should be further understood that the above summary of the invention is not intended to describe every disclosed embodiment or every implementation of the invention. The above description further illustrates illustrative embodiments and provides an explanation of the invention as claimed. In many places throughout the specification, guidance is provided by examples, which can be used in various combinations. In each case, the examples serve only as representative groups and should not be interpreted as exclusive examples. BRIEF DESCRIPTION OF THE DRAWINGS
[0101] The above and other objects, advantages and features of the present invention, as well as the manner in which these objects, advantages and features are achieved, will be readily apparent to those skilled in the art through the following brief description of the drawings, detailed description of the present invention and examples illustrating implementation modes, in which:
[0102] Figure 1A is a schematic diagram of an exemplary Fontan physiology;
[0103] Figure 1B is the screening process (randomization and treatment of participants) used in the Fontan Udenafil Exercise Longitudinal (FUEL) trial as described in Examples 1-2. Peak VO2 (VO2 max) represents oxygen consumption under peak exercise. RER represents respiratory exchange ratio;
[0104] Figure 2A The difference in mean peak or max VO2 change from baseline to week 26 is shown for each treatment group along with the standard deviation. Figure 2B The percentage of subjects (y-axis) who improved peak VO2 by a reference percentage or greater (x-axis) is shown;
[0105] Figure 3A The difference in change in mean VO2 under VAT from baseline to week 26 for each treatment group is shown along with the standard deviation. Figure 3B The percentage of subjects (y-axis) who improved VO2 by the reference percentage or greater (x-axis) under VAT is shown;
[0106] Figure 4A The difference in mean change in power under VAT from baseline to week 26 is shown for each treatment group along with the standard deviation. Figure 4B The percentage of subjects (y-axis) who achieved a reference percentage or greater improvement in power (x-axis) is shown;
[0107] Figure 5 is a schematic diagram of an exemplary Norwood procedure (stage 1) for reconstructing a SVHD heart with hypoplastic left heart syndrome (HLHS);
[0108] Figure 6 is a schematic diagram of an exemplary bidirectional Glenn procedure (stage 2) for reconstructing a SVHD heart with hypoplastic left heart syndrome (HLHS);
[0109] Figure 7 Schematic diagram of an exemplary Fontan procedure (stage 3) for reconstruction of a SVHD heart with hypoplastic left heart syndrome (HLHS) - an extracardiac fenestration Fontan procedure:
[0110] Figure 8 Cumulative incidence plots of primary and secondary outcomes stratified by change in peak oxygen consumption are shown ( Cunningham, 2017 );
[0111] Fig. 9 showed the performance of CPET when stratified by the subsequent primary clinical outcome of death or transplantation (Cunningham, 2017);
[0112] Fig.10 showed the prognostic value of serial CPET testing in Fontan subjects;
[0113] Fig.11 Shows improvement in peak VO2 in the treatment group. ITT analysis of the FUEL trial;
[0114] Fig.12 Improvements in peak VO2 in the treatment group were shown: Analysis of the subgroup of Fontan subjects with baseline predicted peak VO2 <80%;
[0115] Fig.13Improvements in peak VO2 in the treatment groups are shown: Analysis of the subgroup of Fontan subjects with baseline predicted peak VO2 ≥80% (super-Fontan);
[0116] Fig.14 The percent change in peak VO2 by treatment group and FUEL analysis is shown;
[0117] Fig.15 Annualized changes in peak VO2 for treatment groups are shown. Subgroup analysis of Fontan subjects with baseline predicted peak VO2 < 80%;
[0118] Fig.16 Shows the change in peak VO2 after exercise training;
[0119] Fig.17 The improvement of VO2 under VAT in the treatment group in the FUEL ITT analysis is shown;
[0120] Fig.18 The percentage change in VO2 under VAT of the treatment groups in the FUEL ITT analysis is shown;
[0121] Fig.19 Mean changes from baseline in peak or max VO2 (mL / min) in FUEL and FUEL OLE are shown. Placebo = results for participants randomized to placebo in the FUEL trial. Udenafil naive = FUEL OLE results for participants randomized to placebo in the FUEL trial plus newly enrolled participants in the FUEL OLE. Udenafil = FUEL and FUEL OLE results for patients randomized to udenafil in the FUEL trial and continuing with FUEL OLE;
[0122] Fig. 20 Demonstrated the impact of the FUEL trial on statistical endpoints in “Super Fontan” subjects; and
[0123] Fig.21 The effects of the FUEL trial on all secondary endpoints are shown. DETAILED DESCRIPTION
[0124] I. Fontan Physiology
[0125] Fontan physiology is a definitive palliative for those classes of congenital heart defects that share the common feature of a functional single ventricle. They include defects that result in an underdeveloped left or right ventricle. Usually via a series of 2 or 3 surgeries, the systemic and pulmonary circulations are separated to significantly eliminate the mixing of oxygenated and unoxygenated blood caused by congenital heart defects. This is accomplished by connecting the superior and inferior vena cava directly to the pulmonary arteries (i.e., a total cavopulmonary connection). This produces the Fontan physiology that works as follows: (1) the single systemic ventricle pumps oxygenated blood (red blood) from the aorta into the body's systemic arterial vascular beds, (2) systemic venous blood (blue blood) then returns through the venous cavity, the blue blood passively flows through the pulmonary vascular beds, picks up oxygen in the lungs without the aid of the subpulmonary ventricle to oxygenate the blue blood, and (3) the now oxygenated blood (red blood) then returns to the functioning single systemic ventricle pump through the common systemic functioning atrium, and the red blood-blue blood cycle is repeated. This anatomy is shown in Figure 1A and Figure 7 middle.
[0126] The Fontan procedure creates a total cavopulmonary connection, separating the systemic and pulmonary circulations and eliminating both hypoxemia and ventricular volume overload.
[0127] However, after the Fontan procedure, there is no ventricular pump to push blue blood into the pulmonary artery. Instead, blue blood returns to the lungs from the systemic veins via passive flow. Therefore, the main physiological consequence of this type of palliative means is that pulmonary blue blood flow is completely dependent on the pressure gradient from the systemic venous bed to the atrium. Normal circulatory flow through the pulmonary bed is increased by the increased pressure generated by the right ventricle. In healthy adolescents, this causes an increase of about 20mmHg to 25mmHg in the pressure present in the pulmonary artery at rest, which may double in the case of exercise. With Fontan physiology, there is no subpulmonary ventricle, and therefore no pressure increase when blue blood enters the pulmonary artery. At rest, the pressure gradient across the pulmonary vascular bed is significantly smaller. The ability to increase this pressure gradient in the case of exercise is greatly limited by the body's ability to tolerate the gradually rising central venous pressure.
[0128] As a result of its complete reliance on passive drops in venous pressure to drive pulmonary blood flow, Fontan physiology is very sensitive to changes in pulmonary vascular resistance. Even increases in pulmonary resistance within the normal range that are completely within normal physiology will have an adverse effect on Fontan physiology. The use of udenafil provides a unique potential treatment for this type of palliative congenital heart defect. Unlike other uses of PDE-5 inhibitors, this therapy will reduce pulmonary vascular resistance in the population without elevated pulmonary resistance or pressure. The use of this class of drugs is significantly different compared to the following patients: (i) structurally normal heart and pulmonary vascular disease, such as pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD), (ii) heart failure, such as congestive heart disease, or (iii) very rare patients with congenital heart disease and concomitant pulmonary vascular disease that have been palliated by two-ventricle repair (and therefore have a subpulmonary ventricle).
[0129] II. Clinical measurements relevant to Fontan patients
[0130] The Fontan procedure is the current standard of care for children born with a functional univentricular heart or univentricular congenital heart disease. The Fontan procedure is palliative, not curative, and while it has substantially increased the survival of pediatric subjects with functional univentricular heart disease, the procedure also causes a range of side effects and complications that can lead to patient loss, with complications such as arrhythmias, ventricular dysfunction, and the unusual clinical syndromes of protein-losing enteropathy (PLE) and plastic bronchitis, as well as liver and kidney complications.
[0131] In some embodiments, the disclosed invention relates to improving or preventing a decrease in specific clinically relevant physiological measurements indicative of a patient's health after a Fontan procedure. Such measurements include, but are not limited to, exercise testing, vascular function testing, and echocardiographic assessment of ventricular performance.
[0132] III. Exercise test
[0133] Exercise testing can include assessing VO2 values during maximal effort or at the ventilator anaerobic threshold (VAT). VO2 max or maximal oxygen consumption refers to the maximum amount of oxygen an individual can utilize during intense exercise. This measurement is generally considered a reliable indicator of cardiovascular fitness and aerobic endurance. The more oxygen a person can use during high levels of exercise, the more energy that person can produce. This test has become the standard for cardiorespiratory fitness because muscles need oxygen to perform prolonged (aerobic) exercise; the blood carries oxygen to the muscles and the heart must pump enough blood to meet the needs of aerobic exercise.
[0134] VO2 is typically measured by placing a mask on the subject and measuring the volume and gas concentration of the inhaled and exhaled air. This measurement is commonly used in both clinical settings and research and is considered the most accurate. The test typically involves exercising on a treadmill or bicycle ergometer at increasing intensity until exhaustion and is designed to provide a reading at the subject's maximal effort and / or at the subject's anaerobic threshold.
[0135] SVHD patients, including SVHD patients who have previously undergone Fontan surgery, will generally see a decrease in VO2 measurements over time. However, when SVHD patients (including Fontan patients) are practiced or treated using methods according to the present invention, VO2 measurements (i) remain at similar levels, indicating that VO2 measurements have not further decreased, or (ii) improve with therapy, indicating that VO2 has increased, and / or the rate of decrease in VO2 measurements decreases, and therefore, is improved, each indicating that the treatment or method of the present invention is clinically beneficial. In some SVHD patients, treatment according to the present invention can significantly slow or reduce the decrease in VO2 measured during exercise.
[0136] In one embodiment, the present invention relates to a method for improving or maintaining VO2 measurements in SVHD patients or subjects who have undergone Fontan surgery. The method of the present invention comprises administering an effective amount of an effective PDE5 inhibitor to SVHD patients (including Fontan patients), preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof. In some embodiments of the present invention, VO2 is measured at maximum effort, while in other embodiments, VO2 is measured at the anaerobic threshold (VAT) of the subject.
[0137] In some embodiments, the methods and compositions disclosed herein are administered to SVHD patients (including Fontan patients) and result in no or minimal decrease in exercise capacity over time. More specifically, the methods and compositions disclosed herein result in a decrease in exercise capacity over time of less than about 40%, less than about 35%, less than about 30%, less than about 35%, less than about 20%, less than about 15%, less than about 10%, or less than about 5%. The time period between the first measurement and the second measurement used to calculate the decrease in exercise capacity can be, for example, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months or about 12 months; about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, about 11 years, about 12 years, about 13 years, about 14 years, or about 15 years, or any combination thereof, for example 1 year and 3 months; 4 years and 7 months, etc.
[0138] In some embodiments, the methods and compositions disclosed herein can be applied to SVHD patients (including Fontan patients) and improve exercise capacity. More specifically, the methods and compositions disclosed herein can improve VO2 under maximum effort by 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% or more. Alternatively, the methods and compositions disclosed herein can improve VO2 under the ventilatory anaerobic threshold (VAT) of SVHD patients (including Fontan patients) by 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% or more.
[0139] IV. Vascular function tests
[0140] Endothelial dysfunction is an important outcome measure for assessing vascular health in intervention studies. It is now well established that endothelial dysfunction is positively associated with traditional cardiovascular disease (CVD) risk factors and independently predicts cardiovascular events over time intervals of 1 to 6 years.
[0141] Pulse amplitude pressure measurement (PAT) is an FDA-approved method for assessing vascular function, increasingly used as an optional measurement of endothelium-dependent dilation and flow-mediated dilation (FMD) in response to reactive hyperemia. The PAT device uses fingertip plethysmography to record digital pulse wave amplitude (PWA). PWA can be measured continuously during three stages: a quiet baseline period, a 5-minute forearm occlusion, and reactive hyperemia after the cuff is released. Unlike FMD, the PAT test does not rely on highly skilled technicians and the post-test analysis is largely automated. Most importantly, at least one longitudinal study has shown that PAT measurements of endothelial function predict CVD events within a 6-year follow-up period. If prognostic significance and reliability can be verified, these significant advantages can make the PAT test suitable for clinical practice.
[0142] Over time, SVHD patients (including SVHD patients who have undergone the Fontan procedure) will generally see a decline in vascular function. Treating SVHD patients (including Fontan patients) that improves or prevents further decline in vascular function in SVHD patients (including Fontan patients) indicates that the treatment is clinically beneficial and may improve the quality of life of SVHD patients (including Fontan patients) or prevent decline in cardiovascular function.
[0143] In one embodiment, the present invention relates to a method of improving or maintaining vascular function in SVHD patients (including SVHD patients who have previously undergone Fontan surgery). The method comprises administering an effective amount of an effective PDE5 inhibitor to SVHD patients (including Fontan patients), preferably daily, wherein the PDE5 inhibitor is preferably udenafil or a pharmaceutically acceptable salt thereof. In some embodiments, vascular function is measured using the PAT index.
[0144] In some embodiments, administration of the methods and compositions disclosed herein to SVHD patients (including Fontan patients) results in no or minimal decrease in vascular function over time. Vascular function can be measured using any conventional known technique, including but not limited to pulse amplitude pressure measurement, natural logarithm of reactive hyperemia index, reactive hyperemia index, Framingham (RHI), area under the curve to maximum occlusion / control, average up to maximum occlusion / control, and other known EndoPAT indices. In some embodiments of the present invention, vascular function is measured using the PAT index. More specifically, the methods and compositions disclosed herein can result in a decrease in vascular function over time of less than about 40%, less than about 35%, less than about 30%, less than about 35%, less than about 20%, less than about 15%, less than about 10%, or less than about 5%. The time period between the first measurement and the second measurement used to calculate the reduction in vascular function can be, for example, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, or about 12 months; about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, about 11 years, about 12 years, about 13 years, about 14 years, or about 15 years, or any combination thereof, e.g., 1 year and 3 months; 4 years and 7 months, etc.
[0145] In some embodiments, the methods and compositions disclosed herein can be administered to SVHD patients (including Fontan patients) and result in improved vascular function. Vascular function can be measured using any conventional known technique, including but not limited to pulse amplitude pressure measurement, natural logarithm of reactive hyperemia index, reactive hyperemia index, Framingham RHI, area under the curve to maximum occlusion / control, mean up to maximum occlusion / control, and other known EndoPAT indices. In some embodiments of the invention, vascular function is measured using the PAT index. More specifically, the disclosed methods and compositions can provide about 1%, about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or greater improvement in one or more measures of vascular function, including, but not limited to, pulse amplitude tonometry measurements, natural logarithm of reactive hyperemia index, reactive hyperemia index, Framingham RHI, area under the curve to maximum occlusion / control, mean up to maximum occlusion / control, and other known EndoPAT indices. V. Echocardiographic Assessment of Ventricular Performance
[0146] Ventricular performance and cardiac contractility are important measurements that can reveal compromised cardiovascular health before manifesting overt heart failure. Ventricular performance can be assessed using echocardiographic methods and quantified via the Myocardial Performance Index or MPI. The MPI is an index that combines systolic and diastolic function.
[0147] Specifically, MPI is defined as the sum of isovolumetric contraction time and isovolumetric relaxation time divided by ejection time.
[0148] Various versions of MPI are known in the art, each of which can be used to assess ventricular performance. For example, MPI indices may include, but are not limited to, blood pool MPI and tissue Doppler MPI. MPI can be measured using pulsed wave tissue Doppler echocardiography (TDE). To calculate MPI using TDE, the isovolumetric contraction time (IVCT), isovolumetric relaxation time (IVRT), and ejection time (ET) of a normally functioning single ventricle are measured. MPI is then determined by adding the IVCT and IVRT and dividing the sum by the ET.
[0149] Patients who have previously undergone a Fontan procedure will generally see a decline in ventricular performance over time. Treating a patient so that the patient's ventricular performance is maintained, shows minimal decline, or increases over time indicates that the treatment is clinically beneficial and can improve the patient's quality of life or prevent decline in cardiovascular function.
[0150] In one embodiment, the present invention relates to a method of maintaining, minimizing, or increasing ventricular performance in a subject who has previously undergone a Fontan procedure. The method of the present invention comprises administering to the patient a therapeutically effective amount of an effective PDE5 inhibitor, preferably daily, wherein the PDE5 inhibitor is udenafil or a pharmaceutically acceptable salt thereof. In some embodiments of the present invention, ventricular performance is measured using a myocardial performance index (MPI). In some embodiments, the MPI may be a blood pool MPI, while in other embodiments, the MPI may be a tissue Doppler MPI.
[0151] In some embodiments, the methods and compositions disclosed herein can be administered to Fontan patients and result in minimal or no reduction in ventricular performance over time. Ventricular performance can be measured using any conventional known technique, including but not limited to myocardial performance index (MPI), blood pool MPI, tissue Doppler MPI, mean isovolumetric contraction and relaxation, and other known ventricular performance indices. More specifically, the methods and compositions disclosed herein can result in a reduction in ventricular performance over time of less than about 40%, less than about 35%, less than about 30%, less than about 35%, less than about 20%, less than about 15%, less than about 10%, or less than about 5%. The time period between the first measurement and the second measurement used to calculate the reduction in ventricular performance can be, for example, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, or about 12 months; about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, about 11 years, about 12 years, about 13 years, about 14 years, or about 15 years, or any combination thereof, for example 1 year and 3 months; 4 years and 7 months, etc.
[0152] In some embodiments, the methods and compositions disclosed herein can be administered to SVHD patients (including Fontan patients) and result in improved ventricular performance over time. Ventricular performance can be measured using any conventional known technique, including but not limited to myocardial performance index (MPI), blood pool MPI, tissue Doppler MPI, mean isovolumetric contraction and relaxation, and other known ventricular performance indices. For example, the disclosed methods and compositions can result in an improvement in ventricular performance of about 1%, about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more, as measured by any known technique, including but not limited to myocardial performance index (MPI), blood pool MPI, tissue Doppler MPI, mean isovolumetric contraction and relaxation, and other known ventricular performance indices.
[0153] VI. The method according to the invention
[0154] The methods disclosed herein are directed to improving exercise capacity and ventricular performance in SVHD patients (including Fontan patients) who are in need of improved exercise capacity and / or ventricular performance. Generally, the methods comprise administering to SVHD patients (including Fontan patients) daily an effective amount of an effective PDE5 inhibitor or a pharmaceutically acceptable salt thereof, preferably Udenafil or a pharmaceutically acceptable salt thereof, to improve the following:
[0155] (a) Ventricular performance of a single functional normal ventricle in patients with SVHD as measured by MPI;
[0156] (b) exercise capacity as measured by oxygen consumption under VAT;
[0157] (c) exercise capacity as measured by oxygen consumption at maximal effort or VO2max;
[0158] (d) Power consumption under VAT;
[0159] (e) VE / VCO2 under VAT, each individually or in any combination;
[0160] (f) diastolic blood pressure at rest; and
[0161] (g) Oxygen saturation at rest (%), each individually, collectively or in any combination.
[0162] Preferably, the method of the present invention improves the above-listed (a)-(g), including individually, collectively or in any combination thereof. More preferably, according to the present invention, by administering an effective amount of Udenafil or a pharmaceutically acceptable salt thereof to SVHD patients (including Fontan patients) daily, the above-listed (a)-(g), including individually, collectively or in any combination thereof, is improved.
[0163] As described above and used herein, effective PDE5 inhibitors inhibit the degradation of cyclic GMP by cGMP-specific type 5 phosphodiesterases (PDES) in the smooth muscle cells lining the blood vessels supplying blood to various tissues.
[0164] As described above and used herein, MPI is a measure of ventricular systolic and diastolic function as determined by focused echocardiography and is also a prognostic and progression marker for various heart diseases. This value is defined as the sum of the isovolumetric contraction time (ICT) and the isovolumetric relaxation time (IRT) divided by the ejection time (ET) and can be calculated for a single ventricle. Changes in the myocardial performance index are determined by the velocity obtained from Doppler assessment of the blood pool inflow and outflow tracts of a single functioning normal ventricle. In other words, MPI is a measure of the overall systolic and diastolic time intervals used to assess overall cardiac dysfunction and ventricular performance. In addition, since MPI is a Doppler index, it is independent of ventricular geometry and can be applied to left and right ventricular function, depending on which ventricle is a single functioning normal ventricle in a SVHD patient.
[0165] More specifically, these methods comprise daily administration of an effective amount of an effective PDE5 inhibitor or a pharmaceutically acceptable salt thereof, preferably udenafil or a pharmaceutically acceptable salt thereof, to achieve one or more of the above improvements without causing treatment-limiting side effects, including but not limited to blindness or vision loss through inhibition of photoreceptor phosphodiesterase (PDE6), back pain and / or myalgia through inhibition of PDE11 such as 11A1 (PDE11A1), and / or decreased sperm concentration through inhibition of PDE11 such as 11A3 (PDE11). Kayik, G. et al.: Investigation of PDE5 / PDE6 and PDE5 / PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development. Journal of EnzymeInhibition and Medicinal Chemistry, 32(1):311-330 (2017); Pomara G. and Morelli G.: Inhibition of phosphodiesterase 11(PDEII) impacts on sperm quality. Int JImpot Res, 17:385-386 (2005), and Huang SA and Lie, JD.: Phosphodiesterase-5 (PDE5) Inhibitors. In the Management of Erectile Dysfunction. Pharmacy and Therapeutics, 38(7):407-419 (July 2013).
[0166] Quite uniquely and surprisingly, the methods of the present invention increase and / or maximize the ventilatory anaerobic threshold (VAT) and oxygen consumption at maximal effort or VO2max to improve exercise capacity in SVHD patients (including Fontan patients), and increase and / or maximize work power at VAT and VE / VCO2 at VAT.
[0167] Furthermore, it is quite unique and surprising that the methods of the present invention improve the MPI of SVHD patients (i.e., Fontan patients). In other words, the methods of the present invention simultaneously improve the systolic and diastolic function of a single functioning normal ventricle and the overall heart function. In other words, the methods of the present invention improve the filling and emptying characteristics of SVHD patients (including Fontan patients), i.e., the squeezing capacity of a single functioning normal ventricle and the overall capacity of the reconstructed SVHD abnormal heart to pump fresh oxygenated blood to the body to meet the needs of peripheral tissues.
[0168] The clinical value of the improvement in MPI is demonstrated by the statistically significant improvement in MPI in those SVHD patients (particularly Fontan patients) treated with the methods of the present invention compared to those SVHD patients (ie, Fontan patients) treated with placebo during the FUEL trial.
[0169] As mentioned above, the clinical value of MPI improvement is also demonstrated by the improvement in single ventricle performance, as measured by isovolumetric contraction time, isovolumetric relaxation time, and ejection time using TDE.
[0170] "Isovolumetric contraction time" (IVCT) refers herein to a univentricular event occurring early in systole during which a single ventricle contracts without volume change (isovolumetric). This phase of the cardiac cycle, the compression event, occurs when all heart valves are closed.
[0171] "Isovolumetric relaxation time" (IVRT) in this article refers to the interval between the cardiac cycle (i.e., compression and relaxation cycles) from valve closure to the second heart sound of the normal functioning single ventricle starting to fill after the valve opens. IVRT may indicate diastolic dysfunction in a normal functioning single ventricle.
[0172] "Ejection time" (ET) herein refers to the univentricular ejection time (UVET) of a reconstructed abnormal heart, which is determined by the opening and closing of the valve, during which the pressure difference across the valve is measured.
[0173] "Stroke volume" herein refers to the amount of freshly oxygenated blood that a single functioning normal ventricle is able to pump into the circulatory system in one contraction.
[0174] "Cardiac output" in this context refers to the amount of blood that a single functioning normal ventricle in a SVHD patient (including Fontan patients) can pump through the circulatory system in one minute (the average normal adult cardiac output is approximately 4.7 liters (5 quarts) of blood per minute). Stroke volume and heart rate determine cardiac output.
[0175] While each of the improvements in treating SVHD patients, including Fontan patients, according to the methods of the present invention are individually unique and surprising, the combination of improvements in treating SVHD patients, including Fontan patients, is particularly unique and surprising.
[0176] In another embodiment, surprisingly, the methods of the present invention show improved results when Udenafil is administered compared to the very limited studies previously conducted using non-Udenafil PDE5 inhibitors (such as sildenafil or tadalafil). In still another embodiment, surprisingly, the methods of the present invention show fewer side effects and / or less severe side effects when Udenafil is administered compared to other treatments previously using non-Udenafil PDE5 inhibitors (such as sildenafil or tadalafil).
[0177] In some embodiments, the Fontan patient may be an adult, while in other embodiments, the Fontan patient may be a teenager. In some embodiments, the Fontan patient may be between about 12 and about 19 years old, while in other embodiments, the Fontan patient may be between about 12 and about 18 years old. In still other embodiments, the Fontan patient may be between about 12 and about 16 years old. In still other embodiments, the Fontan patient may be between about 6 years old and adult. In one embodiment, the Fontan patient may be less than 18 years old.
[0178] VII. Dosage and Dosage Form
[0179] The structure of Udenafil is shown below:
[0180]
[0181] In some embodiments, Udenafil or a pharmaceutically acceptable salt thereof can be administered at a total daily dose of about 0.01 to about 150 mg / kg. In another embodiment, Udenafil or a pharmaceutically acceptable salt thereof can be administered at a total daily dose of about 0.01 mg / kg to about 30 mg / kg.In another embodiment, Udenafil or a pharmaceutically acceptable salt thereof can be administered at a dose of about 2.5 to about 275 mg, for example, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, about 50 mg, about 52.5 mg, about 55 mg, about 57.5 mg, about 60 mg, about 62.5 mg, about 65 mg, about 67.5 mg. mg, about 70 mg, about 72.5 mg, about 75 mg, about 77.5 mg, about 80 mg, about 82.5 mg, about 85 mg, about 87.5 mg, about 90 mg, about 92.5 mg, about 95 mg, about 97.5 mg, about 100 mg, about 102.5 mg, about 105 mg, about 107.5 mg, about 110 mg, about 112.5 mg, about 115 mg, about 117.5 mg, about 120 mg, about 122.5 mg, about 125 mg, about 127.5 mg, about 130 mg, about 132.5 mg, about 135 mg, about 137.5 mg, about 140 mg, about 142.5 mg , about 145mg, about 147.5mg, about 150mg, about 152.5mg, about 155mg, about 157.5mg, about 160mg, about 162.5mg, about 165mg, about 167.5g, about 170mg, about 172.5mg, about 175mg, about 180mg, about 182.5mg, about 185mg, about 187.5mg, about 190mg, about 192.5mg, about 195mg, about 197.5mg, about 200mg, about 202.5mg, about 205mg, about 207.5mg, about 210mg, about 212.5mg, about 215mg, about 217.5mg , about 220 mg, about 222.5 mg, about 225 mg, about 227.5 mg, about 230 mg, about 232.5 mg, about 235 mg, about 237.5 mg, about 240 mg, about 242.5 mg, about 245 mg, about 247.5 mg, about 250 mg, about 252.5 mg, about 255 mg, about 257.5 mg, about 260 mg, about 262.5 mg, about 265 mg, about 267.5 mg, about 270 mg, about 272.5 mg or about 275 mg, so long as any such individual dose does not result in therapy-limiting toxicity or therapy-limiting side effects such that the drug product would not be approved for marketing.In still another embodiment, Udenafil or a pharmaceutically acceptable salt thereof can be administered at a total daily dose of about 5 mg to about 275 mg, such as about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 87.5 mg, about 90 mg, about 95 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, or about 275 mg, as long as any such single total daily dose does not result in treatment-limiting toxicity or treatment-limiting side effects such that the total daily dose would not be approved for marketing.
[0182] In still another embodiment, Udenafil or a pharmaceutically acceptable salt thereof can be administered at a total daily dose of about 25 mg to about 700 mg, for example, about 25 mg, about 37.5 mg, about 50 mg, about 75 mg, about 87.5 mg, 125 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, or about 700 mg, as long as any such single total daily dose does not result in treatment-limiting toxicity or treatment-limiting side effects such that the total daily dose would not be approved for marketing.
[0183] In a further embodiment, Udenafil or a pharmaceutically acceptable salt thereof can be administered at a total daily dose of about 37.5 mg, about 75 mg, about 87.5 mg, about 125 mg or about 175 mg. In a further embodiment, Udenafil or a pharmaceutically acceptable salt thereof can be administered at a total daily dose ranging from about 37.5 mg to about 175 mg, preferably, the total daily dose ranges from 75 mg to about 175 mg, more preferably, the total daily dose ranges from 87.5 mg to about 175 mg, and most preferably, the total daily dose ranges from 125 mg to about 175 mg. In a preferred embodiment, any dose or any daily total dose of Udenafil or any pharmaceutically acceptable salt thereof can be administered to Fontan patients, as long as any selected single dose or any selected single daily total dose does not result in treatment-limiting toxicity or treatment-limiting side effects. So that the total daily dose will not be approved for marketing.
[0184] Thus, the present invention contemplates administering udenafil or a pharmaceutically acceptable salt thereof to SVHD patients (including Fontan patients) at any dose, any total daily dose, any treatment regimen, and any dosage form, as long as any such dose, total daily dose, treatment regimen, or dosage form is selected without causing treatment-limiting toxicity or treatment-limiting side effects such that it would not be approved for marketing. In particular, the present invention contemplates administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to SVHD patients (including Fontan patients) to improve MPI, single ventricular performance, systolic and / or diastolic function, ventricular compression capacity, cardiac output, exercise capacity or performance at VAT and / or maximum VO2, work capacity at VAT, VE / VCO2 at VAT, diastolic blood pressure at rest, oxygen saturation at rest (%), and / or reduce the rate of decline in SVHD progression compared to untreated SVHD patients, as long as the therapeutically effective amount does not cause treatment-limiting toxicity, treatment-limiting side effects associated with the inhibition of PDE6 and / or PDE11, and / or treatment-limiting side effects such that the drug product would not be approved for marketing.
[0185] In one embodiment, Udenafil or a pharmaceutically acceptable salt thereof may be administered once daily.
[0186] In another embodiment, Udenafil or a pharmaceutically acceptable salt thereof can be administered once a day or in multiple doses, such as twice a day, three times a day, four times a day or more.
[0187] In still another embodiment, Udenafil or a pharmaceutically acceptable salt thereof can be administered twice daily to maintain therapeutically effective blood levels for at least about 1.5 hours to about 24 hours of a 24-hour dosing period, more specifically at least about 1.5 hours, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours. Thus, the present invention contemplates that Udenafil and / or any Udenafil active metabolite, such as DA8164 active metabolite, is maintained at an effective blood level for any period of time within a 24-hour dosing period.
[0188] In some embodiments, the total daily dose of Udenafil or a pharmaceutically acceptable salt thereof administered twice daily may be less than the total daily dose of Udenafil or a pharmaceutically acceptable salt thereof administered once daily.
[0189] In some embodiments, a total daily dose of Udenafil or a pharmaceutically acceptable salt thereof administered twice a day can maintain a therapeutically effective blood level for the same number of hours over a 24-hour period compared to a higher dose of Udenafil or a pharmaceutically acceptable salt thereof administered once a day. In other embodiments, a total daily dose of Udenafil or a pharmaceutically acceptable salt thereof administered twice a day can maintain a therapeutically effective blood level for more hours over a 24-hour period compared to the same dose of Udenafil or a pharmaceutically acceptable salt thereof administered once a day. Therefore, the present invention contemplates administering any total daily dose of Udenafil or any acceptable salt thereof in divided doses once a day or multiple times a day (e.g., twice a day, three times a day, four times a day, or more) to maintain a therapeutically effective blood level over a 24-hour period.
[0190] In one embodiment, surprisingly, administration of Udenafil or a pharmaceutically acceptable salt thereof twice daily results in fewer side effects than administration of Udenafil or a pharmaceutically acceptable salt thereof once daily. In another embodiment, surprisingly, administration of Udenafil or a pharmaceutically acceptable salt thereof twice daily can achieve therapeutically effective levels of Udenafil at a lower total daily dose than once daily administration.
[0191] In some embodiments, the pharmaceutically acceptable salt of Udenafil can be an acid addition salt. In one embodiment, the acid addition salt of Udenafil can be an inorganic acid addition salt, such as hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid addition salt. In another embodiment, the acid addition salt can be an organic acid addition salt, such as citrate, tartrate, acetate, lactate, maleate, fumarate, gluconate, methanesulfonate (mesylate), glycolate, succinate, p-toluenesulfonate (p-toluenesulfonate) (tosylate), galacturonate, pamoate, glutamate, aspartate, oxalate, benzenesulfonate, camphorsulfonate, cinnamate, adipate or cyclamate. In a specific embodiment, the pharmaceutically acceptable salt of Udenafil can be oxalate, benzenesulfonate, camphorsulfonate, cinnamate, adipate or cyclamate.
[0192] In some embodiments, Udenafil or a pharmaceutically acceptable salt thereof can be administered as a pharmaceutical composition. In one embodiment, a pharmaceutical composition comprising Udenafil or a pharmaceutically acceptable salt thereof can be formulated into a variety of oral or parenteral dosage forms in clinical applications. Each of these dosage forms can contain various disintegrants, surfactants, fillers, thickeners, adhesives, diluents (such as wetting agents) or other pharmaceutically acceptable excipients.
[0193] The Udenafil composition can be administered using any pharmaceutically acceptable method, such as intranasally, orally, sublingually, orally, rectally, ocularly, parenterally (intravenous, intradermal, intramuscular, subcutaneous, intramuscular, intraperitoneally), pulmonary, intravaginally, topically administered, topically administered, post-scarring topical administration, mucosal administration, by aerosol, or by oral or nasal gel or spray formulations.
[0194] In addition, the Udenafil composition can be formulated into any pharmaceutically acceptable dosage form, such as a solid dosage form, including but not limited to tablets, pills, lozenges, capsules, caplets, orally disintegrating dosage forms, sublingual dosage forms, buccal dosage forms, liquids, liquid dispersions, liquid suspensions, solutions, aerosols, pulmonary aerosols, nasal aerosols, and semisolids, i.e., ointments, creams, films, and gels, as well as patches, such as transdermal patches.
[0195] Furthermore, the composition can be a controlled release formulation, a sustained release formulation, an immediate release formulation, a modified release formulation, or any combination thereof.
[0196] Additionally, the composition may be a transdermal delivery system.
[0197] In another embodiment, the pharmaceutical composition comprising Udenafil or its pharmaceutically acceptable salt can be formulated into a solid dosage form for oral administration, and the solid dosage form can be a powder, granules, capsules, tablets, capsules, caches, orally disintegrating dosage forms, sublingual dosage forms, oral dosage forms, lozenges or pills. In still another embodiment, the solid preparation can include one or more excipients, such as calcium carbonate, starch, sucrose, lactose, microcrystalline cellulose or gelatin. In addition, in addition to the excipient, the solid dosage form can also include a lubricant such as talc or magnesium stearate. In some embodiments, the oral dosage form can be an immediate release or a modified release. The modified release dosage form includes controlled release, sustained release, modified release or extended release, enteric release, etc. The excipients used in the modified release dosage form are generally known to those of ordinary skill in the art.
[0198] For example, a solid carrier can be one or more substances that can also be used as a diluent, flavoring agent, binder, preservative, oral dosage form disintegrant or encapsulating material. Oral dosage forms, such as powders, granules, capsules, tablets, caplets, cachets, lozenges or pills, preferably contain 5% to 70% of Udenafil. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose (such as lactose monohydrate), pectin, dextrin, starch (such as corn starch), gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, silicon dioxide (such as colloidal silicon dioxide), low melting wax, cocoa butter, etc. The term "product" is intended to include preparations of solid, liquid or semisolid matrices of Udenafil, with or without encapsulating materials.
[0199] Liquid products include solutions, suspensions and emulsions, such as water or water / propylene glycol solutions. For parenteral injection, liquid products can be formulated into solutions of aqueous polyethylene glycol solutions. For example, an aqueous solution suitable for oral use can be prepared by dissolving Udenafil in water and adding appropriate colorants, flavoring agents, stabilizers and thickeners as required. In another example, by dispersing finely dispersed Udenafil in water together with a viscous material (such as natural or synthetic gum, resin, methylcellulose, sodium carboxymethylcellulose and other well-known suspending agents), an aqueous suspension suitable for oral use can be made.
[0200] Also include solid form products, it is intended to be converted into liquid form products for oral administration shortly before use.This liquid form includes solution, suspension and emulsion.In one embodiment, pharmaceutical composition can be formulated into liquid dosage form for oral administration, such as suspension, emulsion or syrup, except Udenafil, it can also contain colorant, flavoring agent, stabilizer, buffer (for example, pH value is adjusted to the buffer of the required range for intravenous use, such as salts of inorganic acids such as phosphate, borate and sulfate), artificial and natural sweetener, dispersant, thickener, solubilizer etc.In other embodiments, in addition to commonly used simple diluents (such as water and liquid paraffin), liquid dosage form can also include various excipients (such as humectants, sweeteners, aromatics or preservatives).In a specific embodiment, the composition comprising Udenafil or its pharmaceutically acceptable salt can be formulated to be suitable for use to pediatric patients.
[0201] In one embodiment, the pharmaceutical composition can be formulated into a dosage form for parenteral administration, such as a sterile aqueous solution, a suspending agent, an emulsion or a non-aqueous solution. In other embodiments, the non-aqueous solution or suspending agent may include propylene glycol, polyethylene glycol, vegetable oil (such as olive oil) or injectable esters, such as ethyl oleate. Alternatively, the pharmaceutical composition can also be formulated into a dosage form for rectal or vaginal administration. As the matrix of a suppository, witepsol, polyethylene glycol (macrogol), tween 61, cocoa butter, laurel oil or glycerin gelatin can be used.
[0202] The pharmaceutical preparation may require a surfactant or other appropriate cosolvent in the composition. Such cosolvents include polysorbate 20, 60 and 80; Pluronic F-68, F-84 and P-103; cyclodextrin; and polyoxyl 35 castor oil. These cosolvents are typically used at a level of between about 0.01% and about 2% by weight. A viscosity greater than that of a simple aqueous solution may be desirable to reduce variability when dispensing the formulation, to reduce physical separation of the suspension or emulsion components of the formulation, and / or to otherwise improve the formulation. Such viscosity enhancers include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxypropyl cellulose, chondroitin sulfate and its salts, hyaluronic acid and its salts, and combinations of the foregoing. These agents are typically used at a level of between about 0.01% and about 2% by weight.
[0203] The pharmaceutical product is preferably in unit dosage form. In this form, the product is subdivided into unit doses containing an appropriate amount of Udenafil or any pharmaceutically acceptable salt thereof. The unit dosage form can be a packaged product, such as a sachet, containing a discrete number of products in the package, such as packaged tablets, caplets, capsules, orally disintegrating dosage forms, sublingual dosage forms, buccal dosage forms, and powders in vials or ampoules. In addition, the unit dosage form can be a capsule, tablet, caplet, pill, orally disintegrating dosage form, sublingual dosage form, buccal dosage form, cachet, or lozenge itself, or can be an appropriate number of any of these dosage forms in packaged form.
[0204] The pharmaceutical compositions may include components that provide immediate release, sustained release, extended release, modified release, convenience and / or comfort. These components include high molecular weight anionic mucoid polymers, gelling polysaccharides and finely dispersed drug carrier matrices.
[0205] In a further embodiment, the pharmaceutical composition comprising Udenafil or a pharmaceutically acceptable salt thereof can be formulated into an orally disintegrating, sublingual or buccal dosage form. Such dosage forms include sublingual tablets or solution compositions for sublingual administration and buccal tablets placed between the cheek and gums.
[0206] Can be by further containing coating agent, for example can produce free radical by ultraviolet light shielding agent, metal oxides such as described titanium oxide, such as free radical scavenger, for example organic acid, such as benzoic acid etc., prepare pharmaceutical preparation.In addition, coating agent can also further include but not limited to, water-soluble polymer (for example, hypromellose (hypromellose) or hydroxypropyl cellulose), contain polyethylene glycol, triethyl citrate, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, methyl methacrylate-methacrylic acid copolymer, shellac, cellulose acetate succinate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, zein, sodium alginate and mannitol, and / or enteric coating aqueous solution, for example comprise ethyl cellulose, medium chain triglyceride, oleic acid, sodium alginate, stearic acid.
[0207] In still further embodiments, the pharmaceutical composition comprising Udenafil or a pharmaceutically acceptable salt thereof can be formulated into a nasal dosage form. Such dosage forms of the present invention include solutions, suspensions, emulsions and gel compositions for nasal delivery.
[0208] In one embodiment, the pharmaceutical composition can be formulated into a liquid dosage form for oral administration, such as a solution, a suspension, an emulsion or a syrup. In other embodiments, in addition to commonly used simple diluents (such as water and liquid paraffin), the liquid dosage form can also include various excipients (such as humectants, sweeteners, aromatics or preservatives). In a specific embodiment, the composition comprising Udenafil or its pharmaceutically acceptable salt can be formulated to be suitable for use in pediatric patients.
[0209] The dosage of the pharmaceutical composition may vary depending on the patient's body weight, age, sex, administration time and method, excretion rate, and severity of the disease.
[0210] VIII. Exercise Test
[0211] Exercise testing may include an assessment of VO2 values during maximal effort or at the ventilator anaerobic threshold (“VAT”). VO2 max (“peak VO2”) or maximal (“peak”) oxygen consumption refers to the maximum amount of oxygen that an individual can utilize during intense exercise. This measurement is generally considered a reliable indicator of cardiovascular fitness and aerobic endurance. In theory, the more oxygen a person can utilize during exercise, the more energy that person can produce. This test is often used to measure cardiopulmonary fitness because muscles require oxygen for prolonged (aerobic) exercise; the blood carries oxygen to the muscles, and the heart must pump sufficient blood to meet the demands of aerobic exercise. However, while peak VO2 can be used as a surrogate marker for many cardiovascular disease states, it may no longer be endpoint-relevant after the Fontan procedure. In this unique physiology, central venous pressure, rather than right ventricular contraction (pumping), is the primary driver of transpulmonary blood flow and, therefore, cardiac output. Gewillig M and Goldberg DJ. Failure of the fontan circulation. Heart FailClin. 10(1): 105-116 (January 2014); Egbe AC, Connolly HM, Miranda WR, Ammash NM, Hagler DJ, Veldtman GR and Borlaug BA. Hemodynamics of Fontan Failure: The Role ofPulmonary Vascular Disease. Circ Heart Fail. 10(12):e004515 (September 2017); Gewillig M, Brown SC, Eyskens B, Heying R, Ganame J, Budts W, La Gerche A and Gorenflo M. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg. 10(3):428-433 (March 2010); and Goldberg DJ, Avitabile CM, McBride MG and Paridon SM. Exercise capacity in the Fontan circulation. Cardiol Young. 23(6): 824-830 (December 2013).Because the demand for cardiac output increases with exertion, central venous pressure in the Fontan circulation must rise to meet this demand, but eventually reaches a critical upper limit, beyond which it cannot rise further. Navaratnam D, Fitzsimmons S, Grocott M, Rossiter HB, Emmanuel Y, Diller GP, Gordon-Walker T, Jack S, Sheron N, Pappachan J, Pratap JN, Vettukattil JJ and Veldtman G. Exercise-Induced Systemic Venous Hypertension in the Fontan Circulation. Am J Cardiol. 117(10): 1667-1671 (May 15, 2016). Under submaximal exertion, the increase in central venous pressure does not reach this physiological upper limit, so the results at this level of exercise may be more sensitive to pharmacological manipulation of the pulmonary vasculature.
[0212] VO2 is typically measured by placing a mask on the subject and measuring the volume and gas concentration of the inhaled and exhaled air. This measurement is commonly used in both clinical settings and research and is considered the most accurate. The test typically involves exercising on a treadmill or bicycle ergometer at increasing intensity until exhaustion and is designed to provide a reading at the subject's maximal effort and / or at the subject's anaerobic threshold.
[0213] Patients who have previously undergone Fontan surgery will generally see a decrease in VO2 measurements over time. Treating a patient with the methods disclosed herein, maintaining the patient's VO2 measurements at similar levels, indicates that VO2 function has not further decreased, or has improved with therapy, indicating that the treatment is clinically beneficial and can improve cardiovascular function or prevent or slow the rate of decline in cardiovascular function.
[0214] IX. Myocardial Performance Index (MPI)
[0215] In general, MPI (also known as Doppler derived index or Tei index) is a measurement of ventricular systolic and diastolic function determined by focused echocardiography. It combines the time intervals of systole and diastole to evaluate cardiac function. More specifically, MPI can be used to evaluate ventricular performance, which is expressed by the value of the cardiac time interval. This value is equal to the sum of the isovolumetric contraction time (ICT) and the isovolumetric relaxation time (IRT) divided by the ejection time (ET) and can be determined for the left or right ventricle. Pellett, AA, et al.: The Tei Index: Methodology and Disease. State Values. Echocardiography: A Jml. of CV Ultrasound & Allied Tech. 21 (7): 669-672 (2004); and Ulugay, A., Tatli E.: Myocardial performance index. Anadolu Kardiyol Derg. 8 (2): 143-8 (April 2008), the entire contents of both articles are incorporated herein by reference. In the FUEL trial, the MPI measurement is the performance of a single functioning normal ventricle. Therefore, the MPI results from the FUEL trial are determined by velocities obtained by blood pool Doppler assessment of the inflow and outflow tracts of a single functioning normal ventricle. In other words, the FUEL trial MPI is determined by measuring cardiac time intervals using pulsed wave Doppler velocity spectra of the ventricular inflow and outflow of a single functioning normal ventricle.
[0216] X. Echocardiography
[0217] Echocardiography was performed by an ultrasound technician who was specially trained in this protocol. The primary outcome of interest was MPI using Doppler-based measurements of inflow and outflow duration. The duration of inflow into the dominant ventricle and outflow through the dominant semilunar valve was measured and used to calculate MPI using a standard formula. Tei C, Ling LH, Hodge DO et al.: New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy. J Cardiol, 26(6): 357-66 (1995); and Pellet AA et al.: The Tei Index: Methodology and Disease State Values. Echocardiography: A Jrnl Of CV Ultrasound & Allied Tech, 21(7): 669-672 (2004). Additional tissue Doppler images were obtained and used to calculate tissue Doppler-based MPI as described previously. Harada K, Tamura M, Toyono M et al.: Comparison of the right ventricular Teiindex by tissue Doppler imaging to that obtained by pulsed Doppler in children without heart disease. Am J Cardiol, 90(5):566-9 (2002). Where possible, three measurements were performed and the average duration was used for calculations.
[0218] XI. Baseline % - predicted maximum or peak value VO2 ≥80% of Super Fontan patients and baseline %-predicted maximum or Peak VO2 Fontan patients with less than 80%
[0219] The FUEL trial in Example 1 below did not exclude Fontan patients based on the upper limit of aerobic exercise capacity (peak or maximum VO2). This trial design resulted in the enrollment of a large number of participants (20% of the analyzable ITT cohort) with a baseline peak VO2 ≥ 80%, and these subjects had normal or near-normal exercise capacity. Until recently, this subgroup of super-Fontan patients was formally recognized in the academic community, and they were referred to as "high performers" or "super-Fontan" (Powell 2020 and Weinreb 2020). When the FUEL trial was designed, it was not fully recognized that these Fontan high performers or super-Fontan patients existed. In addition, the physiological explanation for their unique limitations in exercise was not fully understood. Therefore, therapy with pulmonary vasodilators may not enhance the already high pulmonary vascular reserve (i.e., the fully vasodilated state at baseline) in these Fontan subjects. Therefore, the inclusion of this high performer subgroup may dilute the measurable clinical impact of pulmonary vasodilator therapy on peak VO2 in the overall ITT cohort. The following findings support this assertion and the conclusion of the efficacy of Udenafil in SVHD patients with Fontan cycle palliation: 1. Despite the inclusion of Fontan high performers, the overall ITT results surprisingly showed that the effect of Udenafil on peak VO2 was clinically improved and approached statistical significance (p = 0.092 when peak VO2 was expressed as ml / kg / min and p = 0.071 when expressed as ml / min).
[0220] Baseline %-predicted peak or VO2max influences treatment response. See Figure 2. A robust response was evident in the udenafil group, but only for Fontan patients with a baseline %-predicted peak or VO2max <80%. For patients with a baseline peak VO2 ≥80%, there appeared to be little response at peak or VO2max exercise. Note that responses in the placebo group were negligible across all baseline strata. This concentration of udenafil drug effect in low performers surprisingly provides the greatest opportunity for drug improvement in peak or VO2max exercise capacity for Fontan patients who are at highest risk for adverse clinical events.
[0221] Exclusion of the high-performing Fontan subgroup (peak VO2 ≥ 80% predicted) yielded a cohort with clinically and statistically significant improvements in peak VO2 on udenafil (p = 0.023 for peak VO2 expressed as ml / kg / min; p = 0.030 for peak VO2 expressed as ml / min). This Fontan subgroup represented the majority of subjects enrolled in the FUEL trial (80% of the analyzable ITT cohort) and was the subgroup at highest risk for adverse near-term clinical outcomes (Table 1). These findings are strongly supported by information that was not available when the FUEL trial was planned. Improving pulmonary vasodilatory function in patients with normal pulmonary vasodilatory reserve is simply not feasible, and inclusion of such patients in the FUEL trial would have attenuated the treatment effect.
[0222] Notably, VO2 under VAT was associated with clinically and statistically significant improvements in both the entire ITT cohort (p-0.012) and in the Fontan subgroup that excluded high-performing Fontan subjects (p=0.022). This finding provides mechanistic insight and confirmatory evidence for the efficacy of udenafil in the Fontan cycle: pulmonary vasodilator therapy is able to alter (delay) the shift from aerobic to anaerobic metabolism, but may not further improve peak exercise capacity in super-Fontan patients for the reasons detailed above.
[0223] Over time, even high-performing Fontan subjects deteriorate, with peak or max VO2 falling into the abnormal range. Therefore, it is reasonable to believe that while the use of pulmonary vasodilator therapy will not necessarily improve peak or max VO2 in normal or near-normal (high performers), such therapy may delay or mitigate the inevitable decline in peak VO2 shown in natural history studies of all Fontan patients.
[0224] These methods can be further understood by reference to the following non-limiting examples.
[0225] Example 1
[0226] Fontan Udenafil Exercise Longitudinal (FUEL) trial
[0227] The FUEL trial was conducted at 30 centers worldwide. The FUEL trial was a phase 3 randomized, double-blind, placebo-controlled trial of udenafil in adolescents with SVHD who were treated with Fontan palliative care (funded by Mezzion Pharma Co. Ltd. and conducted by the National Heart, Lung, and Blood Institute-funded Pediatric Heart Network; ClinicalTrials.gov number NCT02741115).
[0228] The primary objective was to determine the effects of udenafil on exercise capacity in adolescents with Fontan physiology over a 6-month period. The primary outcome was the change in oxygen consumption at peak exercise (maximum or peak VO2) from baseline to the Week 26 visit. Secondary exercise outcomes included changes in additional measures at maximal exertion and changes in measures of submaximal exercise at the ventilatory anaerobic threshold (VAT). Primary outcomes of clinical secondary objectives included differences in changes in the myocardial performance index (MPI), an echocardiography-derived measure of systolic and diastolic ventricular function, changes in the log-transformed reactive hyperemia index (lnRHI), a PAT-derived measure of peripheral vascular function, and changes in log-transformed serum BNP levels. Safety was monitored through adverse event reports collected according to a prespecified study coordinator outreach protocol and through ad hoc communication between patients and families and study team members at each site.
[0229] Trial Population
[0230] Individuals aged 12 to 18 years (inclusive), who had undergone a Fontan procedure, were not receiving PDE5 inhibitor therapy, weighed >40 kg, and met the minimum height requirement for the bicycle ergometer (greater than 132 cm) were eligible for enrollment. To isolate the effects of udenafil on exercise performance, patients with severe ventricular dysfunction, severe atrioventricular valvular insufficiency, or those with a peak oxygen consumption less than 50% of that predicted for age and sex on a previous clinical exercise test were excluded. A complete list of inclusion and exclusion criteria is presented in Table 1.
[0231] Table 1 FUEL inclusion and exclusion criteria
[0232]
[0233]
[0234] ALT, alanine aminotransferase; AST, aspartate aminotransferase; CWUA4, cytochrome P450 3A4.
[0235] More specifically, the FUEL trial was designed to evaluate changes in exercise capacity over 26 weeks in patients randomized to receive udenafil vs. placebo. At the time the study was conceived, it was generally accepted that Fontan patients with severely limited exercise capacity (baseline peak or max VO2 <50% predicted) should be excluded from the trial. The rationale for this exclusion was based on: (1) safety; and (2) the belief that this subset of the population was unlikely to provide valid maximal cardiopulmonary exercise testing data. When the FUEL trial was designed, no consideration was given to an upper limit on predicted peak VO2, nor was the possibility of excluding patients with high baseline exercise capacity, as the range of these unique high performers had not yet been identified or understood.
[0236] Importantly, the landscape has changed since the FUEL trial and its design. New information has emerged since the FUEL trial was initiated and after the blinding period was broken. Specifically, four publications recognized that there is a subset of Fontan patients with high exercise capacity. (Cordina 2018, Powell 2019 Year, Weinreb 2020 nianhe Goldberg 2021 )Cordina et al. noted that 14 / 133 (11%) Fontan patients had an exercise capacity of >80% predicted peak VO2. Similarly, Powell determined that 22 / 112 (25%) Fontan patients had high exercise capacity, defined as >80% predicted peak VO2. In retrospect, the FUEL trial should have excluded “high performers,” at least with respect to peak or VO2max testing, because these Fontan patients with higher baseline exercise capacity as assessed by peak cardiopulmonary exercise performance were unlikely to benefit from treatment. Such Fontan high performers do not represent the typical Fontan population. Analysis of a subset of the ITT population excluding Fontan “high performers”—an additional per-protocol analysis—provided statistically significant results for the primary peak or VO2max endpoint (p=0.023) and clinical relevance.
[0237] Randomization and Study Procedures
[0238] Enrolled participants were assigned to udenafil or placebo in a 1:1 ratio using permuted blocks and stratified according to ventricular morphology (left versus right ventricle or mixed). Randomization was generated by a web-based algorithm after confirmation of trial eligibility and consent.
[0239] Baseline clinical testing completed before drug initiation included a blood draw to measure brain natriuretic peptide (BNP) levels, cardiopulmonary exercise testing (CPET) using a standardized bicycle ergometer ramp protocol, standardized echocardiography, and assessment of peripheral vascular function using peripheral arterial tonometry (PAT) measured by a finger cuff (EndoPAT; Itamar Medical, Israel). Participants who achieved maximal effort during CPET (defined as a respiratory exchange ratio (RER) ≥1.10 at peak exercise) were eligible for randomization and initiation of study drug. Participants who did not achieve maximal effort were given a subsequent opportunity to repeat the exercise test within 2 weeks of the first attempt. End-of-study clinical testing included repeated measurements of serum BNP, CPET, echocardiography, and PAT.
[0240] Statistical analysis
[0241] A sample size of 200 participants per group was chosen to allow for a 90% power to detect a mean treatment difference of 10% in the change from baseline to 26-week testing in VO2max with a type 1 error of 0.05. The following assumptions were made: baseline standard deviation of 7.235 ml / kg / min, correlation between VO2max measurements of 0.33, dropout and non-completion rate of 10%, and 15% of participants failing to reach maximal effort on the 26-week exercise test. These assumptions were based on historical data and reflected a conservative approach to assessing within-participant correlation and failure to reach maximal effort.
[0242] The primary analysis used the intention-to-treat population to assess differences in changes in the primary outcome between treatment groups. This difference was assessed by analysis of covariance (ANCOVA) with fixed factors of ventricular morphology (left vs right or mixed) and treatment group, and a continuous covariate of baseline VO2max value. For those without data at the 26-week visit, the value was imputed to be equal to the baseline value (no change). Secondary analyses included participants who successfully completed the protocol and had measurable values for each secondary endpoint. Secondary outcomes for continuous data points were analyzed in the same manner as described for the primary outcomes. To assess the generalizability of the findings at ventilatory anaerobic threshold, demographic and clinical characteristics were compared between participants without paired VO2 data at VAT and those who comprised the rest of the cohort.
[0243] Test results
[0244] Between July 2016 and May 2018, 1376 patients were screened at 30 centers. Figure 1B. Of these, 200 were randomly assigned to udenafil and 200 to placebo. The mean age at randomization was 15.5 years, the mean height was 163.6 cm, and the mean weight was 58.1 kg. 60% of the participants were male, and 81% reported their racial identity as white. Participants in the placebo group were taller than those in the udenafil group, but baseline characteristics were otherwise similar between the groups.
[0245] Primary Objective - Movement Measurements
[0246] Maximal exercise data (VO2 max) were available for all participants at baseline and for 379 participants at 26 weeks (189 in the udenafil group and 190 in the placebo group).
[0247] Reasons for the absence of data at the 26-week test included patient withdrawal or data collection error (n=14), and the inability of participants to produce an RER ≥1.10 (n=7). There were no differences between the udenafil and placebo groups in the change from baseline to the 26-week test in resting heart rate, respiratory rate, or systolic blood pressure. There was a small but statistically significant increase in resting oxygen saturation and a small but statistically significant decrease in diastolic blood pressure in the udenafil group.
[0248] Resting data and exercise performance results are provided in Table 2 .
[0249] Table 2: Comparison of resting data and exercise performance based on treatment group. Summary is presented as mean ± SD (n)*.
[0250]
[0251]
[0252] -*P values estimated using ANCOVA with fixed factors of ventricular morphology (left vs right or mixed) and treatment group and a continuous covariate of baseline VO2max. Note: The last observation carried forward was used to impute missing values at week 26.
[0253] Analysis of resting diastolic blood pressure showed a statistically significant change in diastolic blood pressure (decrease indicating improvement) in the udenafil group (-2.9 decrease, improvement) compared to the placebo group (+0.2 increase, no improvement) (p=0.003).
[0254] Analysis of resting oxygen saturation (%) showed a statistically significant change in oxygen saturation (%) in the udenafil group (+0.5 increase, improvement) compared to the placebo group (-0.3 decrease, no improvement) (increase indicates improvement) (p=0.002).
[0255] Analysis of maximal exercise showed that VO2max increased by 44 mL / min (2.8%) in the udenafil group, compared with a decrease of 3.7 mL / min (-0.2%) in the placebo group, although the difference did not reach statistical significance (p=0.071).
[0256] In addition, as shown in Table 2 above, metabolic data for calculating VO2 under VAT were available for 317 participants, including 170 in the Udenafil group and 181 in the placebo group. Compared with the larger cohort, there were no differences in the baseline demographic characteristics or clinical characteristics of this subgroup. For those patients with paired VO2 data under VAT, the Udenafil group had a statistically significant improvement of 30 mL / min (1.92%), compared with a decrease of 8 mL / min (-0.7%) in the placebo group (p=0.023). Compared with 0.05 (0.2%) in the placebo group, the carbon dioxide ventilation equivalent (VE / VCO2) measured under VAT in the Udenafil group was significantly reduced by 0.8 (2.1%) (ventilatory efficiency was improved) (p=0.011), and compared with 0.31 watts (0.78%) in the placebo group, the Udenafil group significantly improved the power by 3.5 watts (5.5%) (p=0.029). Thus, treatment of Fontan patients with 87.5 mg twice daily demonstrated statistically significant improvements in multiple measures of exercise performance at the ventilatory anaerobic threshold.
[0257] Secondary Target Measurements
[0258] Paired echocardiographic data for MPI measurements were available for 250 participants (63%); 122 in the udenafil group and 128 in the placebo group. Table 3. There was a statistically significant change in MPI (decrease indicating improvement) in the udenafil treatment group (-0.02 decrease, improvement) compared with the placebo group (+0.01 increase, no improvement) (p=0.028).
[0259] Paired PAT-derived vascular function data were available for 328 participants (81%); 163 in the udenafil group and 165 in the placebo group. There was no significant improvement in lnRHI in both the udenafil group and the placebo group (0.07 vs 0.05, p = 0.59). Paired serum BNP level measurements were available for 378 participants (95%); 187 in the udenafil group and 191 in the placebo group. There was no difference in the logarithmic change in serum BNP levels between the groups (p = 0.18). Paired echocardiographic data, paired PAT-derived vascular function data, and paired serum BNP level measurements are provided in Table 3.
[0260] Table 3: Secondary outcomes compared based on treatment group
[0261]
[0262] *P values were estimated using ANOVA with fixed factors of ventricular morphology (left-only vs right-only or mixed) and treatment group
[0263] **P values were estimated using ANCOVA with fixed factors of ventricular morphology (left vs right or mixed) and treatment group and a continuous covariate of baseline VO2max
[0264] ***LS means (least square means) are the treatment mean differences estimated by the analysis model
[0265]
[0266]
[0267] ANCOVA = analysis of covariance; ITT = intention to treat; LS = least squares; SD = standard deviation; SE = standard error. P values were estimated using ANCOVA with fixed factors of ventricular morphology (left-only vs right-only or mixed) and treatment group and a continuous covariate of baseline maximum minute oxygen consumption.
[0268] Note: Laboratory-reported BNP values <2.0 were estimated to be 1.0.
[0269] Safety and Tolerability
[0270] Table 4: Non-serious adverse events. Number of participants experiencing adverse events, expressed as n (%).
[0271]
[0272] *Percentage of male participants.
[0273] Udenafil and placebo were well tolerated by study participants. There were no deaths in the study cohort. A total of 24 participants (6%) experienced serious adverse events; 14 in the udenafil group and 10 in the placebo group. Three events in the udenafil group and two in the placebo group were considered possibly, probably, or definitely related to the study drug. Those events that occurred in the udenafil group included unilateral retinal arteriovenous thrombosis, transient paraplegia, and transient dyspnea. Table 4 provides frequent non-serious adverse events that were considered possibly, probably, or definitely related to the study drug and occurred in at least 5% of participants in either treatment group. Headache, facial flushing, abdominal pain, epistaxis, and erection (male participants) were more common in the udenafil group. All other adverse events occurred at similar frequencies between groups.
[0274] Example 2
[0275] Additional FUEL Test Results
[0276] The following examples additionally describe the above-described FUEL assay, as referenced in Goldberg, DJ, et al.: Results of the Fontan Udenafil Exercise Longitudinal (FUEL) Trial. Circulation, 141(8): 141:641-651 (2020), which is hereby incorporated by reference in its entirety.
[0277] The Fontan procedure creates a total cavopulmonary connection, a circuit in which the importance of pulmonary vascular resistance is magnified. Over time, this circuit can lead to reduced cardiovascular efficiency that is associated with decreased athletic performance.
[0278] Rigorous clinical trials aimed at improving physiological function and guiding drug therapy are currently lacking.
[0279] The FUEL trial was a phase III clinical trial conducted at 30 centers. Participants were randomly assigned in a 1:1 ratio to udenafil (87.5 mg twice daily) or placebo. The primary outcome was the between-group difference in change in oxygen consumption at peak exercise. Secondary outcomes included between-group differences in change in submaximal exercise at ventilatory anaerobic threshold (VAT), myocardial performance index (MPI), natural logarithm of reactive hyperemia index (lnRHI), and serum brain natriuretic peptide (BNP).
[0280] Between 2017 and 2019, 400 participants with Fontan physiology were randomized at 30 clinical sites in North America and South Korea. The mean age at randomization was 15.5±2 years; 60% of participants were male and 81% were white. All 400 subjects were included in the primary analysis, and the week 26 endpoint was imputed for 21 subjects with missing data (11 subjects randomized to udenafil and 10 subjects to placebo). Among randomized participants, peak oxygen consumption increased by 44±245 mL / min (2.8%) in the udenafil group and decreased by 3.7±228 mL / min (-0.2%) in the placebo group (p=0.071). Analysis of VAT showed that the udenafil group had statistically significant improvements in oxygen consumption (+33±185 (3.2%) vs -9±193 (-0.9%) mL / min, p=0.012), carbon dioxide ventilatory equivalent (-0.8 vs -0.06, p=0.014), and power (+3.8 vs +0.34 watts, p=0.021) compared with the placebo group. MPI analysis also showed that the udenafil treatment group had a statistically significant improvement in MPI compared with the placebo group over the same time period (p=0.028). There were no differences in changes in lnRHI or serum BNP levels.
[0281] In the FUEL trial, treatment with udenafil (87.5 mg twice daily) was associated with improved oxygen consumption at peak exercise (p = 0.071) and statistically significant improvements in: (i) multiple measures of exercise performance at the ventilatory anaerobic threshold (VAT), (ii) MPI, (iii) resting diastolic blood pressure, and (iv) resting oxygen saturation (%).
[0282] The FUEL trial was funded by Mezzion Pharma Co. Ltd. and conducted by the Pediatric Heart Network funded by the National Heart, Lung, and Blood Institute, Clinica1Tria1s.gov No. NCT02741115, which is hereby incorporated by reference in its entirety.
[0283] Clinical prospects
[0284] New aspects
[0285] · Circulation publication describing results of the Fontan Udenafil Exercise Longitudinal (FUEL) trial, the largest medical intervention trial in congenital heart disease. Goldberg DJ et al.: Results of the FUEL Trial. Circulation, 141(8):141:641-651 (2020)
[0286] Goldberg DJ et al.: Results of the FUEL Trial. Circulation, 141(8):141:641-651 (2020), erratum to Circulation, incorporated into Example 4, describing the corrected MPI results for the FUEL trial.
[0287] Although treatment with udenafil did not result in a statistically significant increase in peak oxygen consumption, it did result in a noteworthy increase in peak oxygen consumption.
[0288] Treatment with udenafil did result in statistically significant improvements in the following measures: exercise performance at ventilator anaerobic threshold (VAT), power output at VAT, ventilatory equivalent of carbon dioxide at VAT (VE / VCO2), MPI, diastolic blood pressure at rest, and oxygen saturation at rest.
[0289] Udenafil was well tolerated by FUEL trial participants, with side effects limited to those previously known to be associated with PDE5 inhibitors.
[0290] Clinical significance
[0291] Udenafil is the first drug evaluated in a large-scale Phase III clinical trial to demonstrate quantifiable benefits on measures of motor performance in adolescents following Fontan palliation.
[0292] The inventions demonstrate that therapy with udenafil improves physiology, exercise capacity, power, VE / VCO2, MPI, cardiac output, compression performance, flow that can circulate through the body in a given amount of time, diastolic blood pressure and / or oxygen saturation at rest, and performance of a single functioning normal ventricle in a cohort of patients undergoing total cavopulmonary connection.
[0293] Ongoing monitoring is needed to determine the effects of chronic treatment with udenafil on the long-term clinical course of those patients with univentricular congenital heart disease.
[0294] Children born with single ventricle congenital heart disease (SVHD) require a series of staged surgical interventions to reconstruct their defective hearts for long-term survival. The Fontan procedure is the last planned palliative procedure in this series of staged surgical interventions to reconstruct the heart, which separates the systemic and pulmonary circulations by establishing a total cavopulmonary connection. Fontan F and Baudet E. Surgical repair of tricuspid atresia. Thorax. 26(3): 240-248 (May 1971); and Kreutzer G, Galindez E, Bono H, De Palma C, and Laura JP. An operation for the correction of tricuspid atresia. The Journal of thoracic and cardiovascular surgery. 66(4): 613-621 (October 1973).
[0295] However, in the absence of a subpulmonary pump, the resulting Fontan circulation is characterized by passive pulmonary blood flow, chronically elevated central venous pressure, and low cardiac output. Gewillig M and Goldberg DJ. Failure of the fontan circulation. Heart Fail Clin. 10(1): 105-116 (January 2014); Egbe AC, Connolly HM, Miranda WR, Ammash NM, Hagler DJ, Veldtman GR and Borlaug BA. Hemodynamics of Fontan Failure: The Role of Pulmonary Vascular Disease. Circ Heart Fail. 10(12): e004515 (September 2017); Gewillig M, Brown SC, Eyskens B, Heying R, Ganame J, Budts W, LaGerche A and Gorenflo M. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg. 10(3):428-433 (March 2010); and Goldberg DJ, Avitabile CM, McBride MG and Paridon SM. Exercise capacity in the Fontan circulation. Cardiol Young. 23(6):824-830 (December 2013). Although Fontan physiology is generally well tolerated in childhood, cardiovascular efficiency deteriorates during adolescence and into adulthood. Dennis M, Zannino D, duPlessis K, Bullock A, Disney PIS, Radford DJ, Homung T, Grigg L, Cordina R, d'Udekem Y and Celermajer DS. Clinical Outcomes in Adolescents and Adults After the Fontan Procedure. JAm Coll Cardiol.71(9):1009-1017 (March 6, 2018); Fernandes SM, McElhinney DB, Khairy P, Graham DA, Landzberg MJ and Rhodes J. Serial cardiopulmonary exercise testing in patients with previous Fontan surgery. Pediatr Cardiol. 31(2):175-180 (February 2010); Giardini A, Hager A, Pace Napoleone C and Picchio FM. Natural history of exercise capacity after the Fontan operation: a longitudinal study. Ann Thorac Surg. 85(3):818-21 (March 2008); Jenkins PC, Chinnock RE, Jenkins KJ, Mahle WT, Mulla N, Sharkey AM and Flanagan MF. Decreased exercise performance with age in children with hypoplastic left heart syndrome. J Pediatr. 152(4):507-512 (April 2008); Paridon SM, Mitchell PD, Colan SD, Williams RV, Blaufox A, Li JS, Margossian R, Mital S, Russell J, Rhodes J and Pediatric Heart Network I. A cross-sectional study of exercise performance during the first 2 decades of life after the Fontan operation. J Am Coll Cardiol.52(2):99-107 (July 8, 2008); and Atz AM, Zak V, Mahony L, Uzark K, D'Agincourt N, Goldberg DJ, Williams RV, Breitbart RE, Colan SD, Burns KM, Margossian R, Henderson HT, Korsin R, Marino BS, Daniels K, McCrindle BW and Pediatric Heart Network I. Longitudinal Outcomes of Patients With Single Ventricle After the Fontan Procedure. J Am Coll Cardiol. 69(22):2735-2744 (June 6, 2017). This deterioration is associated with a decrease in exercise capacity, global cardiac performance, single ventricular performance, and an increase in the prevalence of heart failure symptoms, hospitalization, and mortality. Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP and Gatzoulis MA. Exercise intolerance in adult congenital heart disease: comparable severity, correlates, and prognostic implication.Circulation.112(6):828-35 (August 9, 2005); Diller GP, Giardini A, Dimopoulos K, Gargiulo G, MullerJ, Derrick G, Giannakoulas G, Khambadkone S, Lammers AE, Picchio FM, Gatzoulis MA and Hager A. Predictors of morbidity and mortality in contemporary times Fontanpatients:results from amulticenter study including cardiopulmonary exercisetesting in 321patients.Eur Heart J.31(24):3073 - 3083 (December 2010); Downing TE, Allen KY, Glatz AC, Rogers LS, Ravishankar C, Rychik J, Faerber JA, Fuller S, Montenegro LM, Steven JM, Spray TL, Nicolson SC, Gaynor JW and Goldberg DJ. Long - term survival after the Fontan operation: Twenty years of experience at a single center. The Journal of thoracic and cardiovascular surgery. 154(1):243 - 253e2 (July 2017); Khairy P, Fernandes SM, Mayer JE, Jr., Triedman JK, Walsh EP, Lock JE and Landzberg MJ. Long - term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 117(1):85 - 92 (January 1, 2008); Pundi KN, Johnson JN, Dearani JA, Pundi KN, Li Z, Hinck CA, Dahl SH, Cannon BC, O'Leary PW, Driscoll DJ and Cetta F. 40 - Year Follow - Up After the Fontan Operation: Long - Term Outcomes of 1,052 Patients. J Am Coll Cardiol. 66(15):1700 - 1710 (October 13, 2015); Cunningham JW, Nathan AS, Rhodes J, Shafer K, Landzberg MJ and Opotowsky AR. Decline in peak oxygen consumption over time predicts death or transplantation in adults with a Fontan circulation. Am Heart J.189:184-192 (July 2017); and Udholm S, Aldweib N, Hjortdal VE and Veldtman GR. Prognostic power of cardiopulmonary exercise testing in Fontan patients: a systematic review. Open Heart. 5(1):e000812 (July 2018). .
[0296] After the Fontan procedure, pulmonary blood flow is determined by the relationship between central venous pressure, pulmonary vascular resistance, and systemic atrial pressure. In this configuration, the role of pulmonary vascular resistance as a regulator of pulmonary blood flow and single ventricular preload is amplified and is critical to circulatory efficiency. Gewillig M and Goldberg DJ., Failure of the fontancirculation. Heart Fail Clin. 10(1): 105-116 (January 2014); Egbe AC, Connolly HM, Miranda WR, Ammash NM, Hagler DJ, Veldtman GR and Borlaug BA. Hemodynamics of Fontan Failure: The Role of Pulmonary Vascular Disease. Circ Heart Fail.10(12):e004515 (September 2017); Gewillig M, Brown SC, Eyskens B, Heying R, Ganame J, Budts W, LaGerche A and Gorenflo M. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg. 10(3):428-433 (March 2010); and Goldberg DJ, Avitabile CM, McBride MG and Paridon SM. Exercise capacity in the Fontan circulation. Cardiol Young. 23(6):824-830 (December 2013). Previous reports have explored the administration of pulmonary vasodilators, including phosphodiesterase type 5 (PDE5) inhibitors, with mixed results. Agnoletti G, Gala S, Ferroni F, Bordese R, Appendini L, Pace Napoleone C and Bergamasco L. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation.《胸心血管外科杂志》,第153卷第6期:1468 - 1475页(2017年6月);戈德堡DJ、弗伦奇B、麦克布赖德MG、马里诺BS、米拉奇N、汉纳BD、韦莫夫斯基G、帕里登SM和里基克J。口服西地那非对Fontan手术后儿童和年轻人运动能力的影响:一项随机、双盲、安慰剂对照、交叉试验,《循环》,第123卷第11期:1185 - 1193页(2011年5月22日);赫伯特A、米克尔森UR、蒂伦U、伊登L、延森AS、纳吉E、汉修斯K、索伦森KE和桑德加德L。波生坦改善Fontan手术后青少年和成年人的运动能力:TEMPO(Fontan患者内皮素受体拮抗剂治疗,一项测量峰值耗氧量的随机、安慰剂对照、双盲研究)研究。《循环》,第130卷第23期:2021 - 2030页(2014年12月2日);森H、朴IS、山岸H、中村M、石川S、滝木K、安河内S、中山T、佐治T和中西T。西地那非降低单心室生理状态下的肺血管阻力。《国际心脏病学杂志》221:122 - 127 (October 15, 2016); Rhodes J, Ubeda - Tikkanen A, Clair M, Fernandes SM, Graham DA, Milliren CE, Daly KP, Mullen MP and Landzberg MJ. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol. 168(3):2435 - 2440 (October 3, 2013); Schuuring MJ, Vis JC, van Dijk AP, van Melle JP, Vliegen HW, Pieper PG, Sieswerda GT, de Bruin - Bon RH, Mulder BJ and Bouma BJ. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 15(6):690 - 698 (June 2013); Tunks RD, Barker PC, Benjamin DK, Jr., Cohen - Wolkowiez M, Fleming GA, Laughon M, Li JS and Hill KD. Sildenafil exposure and hemodynamic effect after Fontan surgery. Pediatr CFU Care Med. 15(1):28 - 34 (January 2014); Van De Bruaene A, La Gerche A, Claessen G, De Meester P, Devroe S, Gillijns H, Bogaert J, Claus P, Heidbuchel H, Gewillig M and Budts W. Sildenafil exposure and hemodynamic effect after Fontan surgery.Circ Cardiovasc Imaging, 7(2):265-273 (March 2014); Goldberg DJ, French B, Szwast AL, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM and Rychik J. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Pediatr Cardiol, 33(5):689-696 (June 2012); and Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M and Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 29(13):1681-1687 (July 2008).
[0297] Previously, a phase I / II study of the long-acting PDE5 inhibitor udenafil (Mezzion Pharma Co. Ltd., Seoul, South Korea) has been completed in adolescents with Fontan physiology and showed that all tested dosing regimens were well tolerated. Goldberg DJ, Zak V, Goldstein BH, Chen S, Hamstra MS, Radojewski EA, Maunsell E, Mital S, Menon SC, Schumacher KR, Payne RM, Stylianou M, Kaltman JR, deVries TM, Yeager JL., Paridon SM and Pediatric Heart Network I. Results of a phase I / II multi-center investigation of Udenafil in adolescents after fontanpalliation. Am Heart J. 188:42-52 (June 2017). The dose of 87.5 mg twice daily was associated with the highest mean serum concentrations and was not associated with dose-limiting adverse events. In the Pediatric Heart Network (PHN) Fontan Udenafil Exercise Longitudinal (FUEL) trial (NCT02741115), we evaluated the effects of udenafil on exercise performance and other cardiovascular and functional outcomes over a 6-month period in adolescents receiving Fontan palliative care.
[0298] method
[0299] The FUEL trial was an international, multicenter, randomized, double-blind, placebo-controlled trial of udenafil in addition to standard care in adolescents with SVHD receiving Fontan palliative care. The trial was supported by the PHN, funded by the National Heart, Lung, and Blood Institute (NHLBI), in collaboration with the regulatory sponsor, Mezzion Pharma Co. Ltd., and was conducted under a Special Protocol Assessment by the Food and Drug Administration. The FUEL protocol and consent form, and all subsequent amendments, were approved by the DSMB, the institutional review board or equivalent at each site, and regulatory agencies in the United States, Canada, and South Korea. Permission was obtained from study participants or legal guardians of participants younger than 18 years of age. Written consent was obtained from participants older than 18 years of age. The trial design has been published previously. Goldberg DJ,Zak V,Goldstein BH,McCrindle BW,Menon SC,Schumacher KR,PayneRM,Rhodes J,McHugh KE,Penny DJ.Trachtenberg F,Hamstra MS,Richmond ME,FrommeltPC,Files MD,Yeager JL,Pemberton VL,Stylianou MP,Pearson GD,Paridon SM andPediatric Heart Network I.Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial. Am Heart J. 201:1-8 (July 2018).
[0300] Trial Population
[0301] Individuals aged 12 to 18 years, inclusive, who had undergone a Fontan procedure, were not receiving PDE5 inhibitor therapy, weighed greater than 40 kg, and met the minimum height requirement for the bicycle ergometer (greater than 132 cm) were eligible for enrollment. To isolate the effects of udenafil on exercise performance, patients with severe ventricular dysfunction, severe atrioventricular valvular insufficiency, or those with a peak oxygen consumption less than 50% of the predicted value based on age and sex on a previous clinical exercise test were excluded. A complete list of the inclusion and exclusion criteria for the study protocol is presented in Table 1 above.
[0302] Randomization and Study Procedures
[0303] Enrolled participants were assigned to udenafil or placebo in a 1:1 ratio in a double-blind manner using randomized permuted blocks and stratified according to ventricular morphology (left versus right ventricle or mixed). Randomization was generated by a web-based algorithm after confirmation of trial eligibility and consent.
[0304] Baseline clinical tests completed before drug initiation included a blood draw to measure brain natriuretic peptide (BNP) levels, cardiopulmonary exercise testing (CPET) using a standardized bicycle ergometer ramp protocol (previously described in children and adolescents with Fontan physiology, Sleeper LA, Anderson P, Hsu DT, Mahony L, McCrindle BW, Roth SJ, Saul JP, Williams RV, Geva T, Colan SD. Clark BJ and Pediatric Heart Network I. Design of a large cross-sectional study to facilitate future clinicaftrials in children with the Fontan palliation. Am Heart J. 152(3):427-433 (September 2006)), standardized echocardiography, and assessment of peripheral vascular function using peripheral arterial tonometry (PAT) measured by a finger cuff (EndoPAT; Itamar Medical, Israel). Participants who achieved maximal effort (defined as respiratory exchange ratio (RER) > 1.10 at peak exercise) during CPET were eligible for randomization and initiation of study medication. Participants who did not achieve maximal effort were given a subsequent opportunity to repeat the exercise test within two weeks of the first attempt. End-of-study clinical testing included repeated measurements of serum BNP, CPET, echocardiography, and PAT.
[0305] Primary and Secondary End Points
[0306] The primary objective was to determine the effects of udenafil on exercise capacity in adolescents with Fontan physiology over a 6-month period. The primary outcome was the between-group difference in the change from baseline to the 26-week visit in oxygen consumption at peak exercise (peak VO2). Secondary exercise outcomes included between-group differences in the change in additional measurements of maximal exertion and the change in measurements of submaximal exercise at the ventilatory anaerobic threshold (VAT). All measurements of exercise test values were initially performed by an exercise physiologist and physician at each participating site. They were subsequently reviewed for accuracy at each site by one of two trained reviewers (MGM, SMP) in conjunction with the exercise team at each site before finalization. Non-indexed oxygen consumption was assessed for both peak VO2 and VO2 at VAT to avoid confounding based on short-term changes in physical habituation. The analysis of oxygen consumption corrected for body weight is included in Table 5.
[0307] Table 5: Comparison of peak exercise and anaerobic threshold oxygen consumption indexed to body weight based on treatment group. Summary is presented as mean ± SD (n).
[0308]
[0309] **P_values were estimated using ANCOVA with fixed factors of ventricular morphology (left vs right or mixed) and treatment group and a continuous covariate of baseline VO2max. Estimated as follows:
[0310] Subjects known to be alive but discontinued from the study (missing VO2max at Week 26) will be assigned the latest available value (e.g., the value at the end of study visit if available, otherwise the value at the baseline visit).
[0311] Subjects who completed Week 26 but were physically unable to reach maximal effort on cardiopulmonary exercise testing after two attempts were assigned the baseline value when the subject reached maximal effort on the baseline exercise test. One exception was subject 330011, who was judged to be included because the RER was 1.10.
[0312] The primary outcomes of clinical secondary objectives included between-group differences in change in myocardial performance index (MPI), an echocardiography-derived measure of systolic and diastolic ventricular function, between-group differences in change in log-transformed reactive hyperemia index (lnRHI), a PAT-derived measure of peripheral vascular function, and between-group differences in change in log-transformed serum BNP levels. Measurement of each of these secondary outcomes was performed in the core laboratory. Safety was monitored through adverse event reports collected according to a prespecified study coordinator outreach protocol and through ad hoc communication between patients and families and members of the study team at each site.
[0313] Statistical analysis
[0314] A sample size of 200 participants per group was chosen to allow for a 90% power to detect a mean treatment difference of 10% in the change in peak VO2 from baseline to the 26-week test with a type 1 error of 0.05. We assumed a baseline standard deviation of 7.235 ml / kg / min, a correlation of 0.33 between peak VO2 measurements, a dropout and non-testing rate of 10%, and 15% of participants failing to reach maximal effort on the 26-week exercise test. These assumptions were based on historical data, reflected a conservative approach to assessing within-participant correlation and failure to reach maximal effort, and were analyzed using a two-sample independent means t-test. The primary analysis used the intention-to-treat population to assess differences in the change in the primary outcome between treatment groups. This difference was assessed by analysis of covariance (ANCOVA) with fixed factors for ventricular morphology (left-only vs right-only or mixed) and treatment group, and a continuous covariate for baseline peak VO2. For those patients without data at the 26-week visit, the value was imputed to be equal to the baseline value (no change). The alpha level was set at 0.05, with a two-sided test. All statistical analyses were performed using SAS statistical software 9.4 (SAS Institute, Inc., Cary, North Carolina). Secondary analyses included participants who successfully completed the protocol and had measurable values for each secondary endpoint. Secondary outcomes with continuous data points were analyzed in the same manner as described for the primary outcomes. To assess the generalizability of the findings at the ventilatory anaerobic threshold, demographic and clinical characteristics were compared between participants without paired VO2 data at VAT and those who comprised the rest of the cohort using Student's t-test and Fisher's exact test. Fisher's exact test was used to compare adverse events between the udenafil and placebo cohorts.
[0315] result
[0316] Participants: Between July 2016 and May 2018, 1376 patients were screened at 30 centers. Figure 1B Of these, 200 were randomized to udenafil and 200 to placebo. The mean age at randomization was 15.5 years, the mean height was 163.6 cm, and the mean weight was 58.1 kg. 60% of the participants were male, and 81% described their racial identity as white. In Table 6, participants in the placebo group were taller compared with the udenafil group, but baseline characteristics were otherwise similar between the groups.
[0317] Table 6: Demographic and clinical baseline characteristics of the 400 subjects randomized to treatment groups; summaries are presented as mean (standard deviation) unless otherwise noted as n (%).
[0318]
[0319]
[0320] * Continuous variables were analyzed using t test, and categorical variables were analyzed using Fisher's exact test.
[0321] Movement measurements
[0322] Resting, submaximal, and maximal exercise measures are listed in Table 2 . Maximal exercise data were available for all participants at baseline and for 379 participants at week 26 (189 in the udenafil group and 190 in the placebo group). Reasons for the absence of data at week 26 included patient withdrawal or data collection errors (n = 14) and the inability of participants to produce an RER greater than 1.10 (n = 7). There were no differences between the udenafil and placebo groups in the change from baseline to week 26 in resting heart rate, respiratory rate, or systolic blood pressure. Peak minute ventilation at baseline (before drug exposure) was higher in the placebo group, but there was no difference in the change in minute ventilation between the groups. There was a small but statistically significant increase in resting oxygen saturation and a small but statistically significant decrease in diastolic blood pressure in the udenafil group.
[0323] Analysis of maximal exercise showed that peak VO2 increased by 44 mL / min (2.8%) in the udenafil group, compared with a decrease of 3.7 mL / min (-0.2%) in the placebo group, but the difference did not reach statistical significance. Figure 2A-2B , p=0.071. Metabolic data were available for calculation of VO2 under VAT for 351 participants, including 170 in the udenafil group and 181 in the placebo group. There were no differences in baseline demographics or clinical characteristics in this subgroup compared with the larger cohort. Table 7. For those patients with paired VO2 under VAT data, there was a statistically significant improvement of 29.7 mL / min (2.85%) in the udenafil group, compared with a decrease of 9 mL / min (-0.8%) in the placebo group. Figure 3A-3B , p = 0.023. The carbon dioxide ventilatory equivalent (VE / VCO2) measured at VAT in the udenafil group was significantly reduced by 0.8 (improved ventilatory efficiency) compared with 0.05 in the placebo group (p = 0.0114), while the power of operation in the udenafil group was significantly improved by 3.5 watts (5.2%) compared with 0.31 watts (0.5%) in the placebo group. Figures 4A-4B , p=0.029.
[0324] Table 7: Demographic and clinical baseline characteristics of subjects with and without paired VO2 data under VAT; summaries are presented as mean (standard deviation) unless otherwise noted as n (%).
[0325]
[0326]
[0327] * Continuous variables were analyzed using t-tests and categorical variables were analyzed using Fisher’s exact test.
[0328] Secondary Objectives
[0329] Paired echocardiographic data for MPI measurements were available for 250 participants (63%); 122 in the udenafil group and 128 in the placebo group. Table 3. There was a statistically significant change in MPI (decrease indicating improvement) in the udenafil treatment group (-0.02 decrease, improvement) compared with the placebo group (+0.01 increase, no improvement) (p = 0.028). Paired PAT-derived vascular function data were available for 328 participants (81%); 163 in the udenafil group and 165 in the placebo group. There was no significant improvement in lnRHI in both the udenafil and placebo groups (0.07 vs 0.05, p = 0.59). Paired measurements of serum BNP levels were available for 378 participants (95%); 187 in the udenafil group and 191 in the placebo group. There was no difference in the change in log serum BNP levels between the groups (p=0.18).
[0330] Safety and Tolerability
[0331] Udenafil and placebo were well tolerated by study participants. There were no deaths in the study cohort. A total of 24 participants (6%) experienced serious adverse events; 14 in the udenafil group and 10 in the placebo group. Three events in the udenafil group and two in the placebo group were considered possibly, probably, or definitely related to the study drug. Those events that occurred in the udenafil group included unilateral retinal arteriovenous thrombosis, transient paraparesis, and transient dyspnea. Frequent non-serious adverse events that were considered possibly, probably, or definitely related to the study drug are listed in Table 4. Headache, facial flushing, abdominal pain, epistaxis, and erection (male participants) were more common in the udenafil group. There were no reports of episodes of priapism. All other adverse events occurred with similar frequencies between groups.
[0332] discuss
[0333] The FUEL trial was a phase III clinical trial of udenafil in children with SVHD undergoing the Fontan procedure. Although the relative improvement in peak VO2 in the udenafil group did not reach statistical significance when compared between treatment groups, treatment with udenafil did result in a statistically significant improvement in the prespecified secondary outcome measure of submaximal exercise. Participants randomized to udenafil experienced superior benefits in oxygen consumption, power, ventilatory efficiency at anaerobic threshold, and myocardial performance index. No relative improvement in the PAT-derived reactive hyperemia index was seen. Overall, udenafil was well tolerated, with few serious adverse effects, and side effects limited to those known to be associated with PDE5 inhibitor therapy.Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM and Rychik J. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 123(11):1185 - 1193 (May 22, 2011); Goldberg DJ, Zak V, Goldstein BH, McCrindle BW, Menon SC, Schumacher KR, Payne RM, Rhodes J, McHugh KE, Penny DJ, Trachtenberg F, Hamstra MS, Richmond ME, Frommelt PC, Files MD, Yeager JL, Pemberton VL, Stylianou MP, Pearson GD, Paridon SM and Pediatric Heart Network I. Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial. Am Heart J. 201:1 - 8 (July 2018); and Chang HJ, Song S, Chang SA, Kim HK, Jung HO, Choi JH, Lee JS, Kim KH, Jeong JO, Lee JH and Kim DK. Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial. Clin Ther. 41(8):1499 - 1507 (August 2019).
[0334] Although the Fontan procedure and its modifications have enabled a generation of patients with otherwise end-stage SVHD to survive, the circulation established by this procedure has inherent physiological defects: chronically elevated central venous pressure and chronically reduced cardiac output. Gewillig M and Goldberg DJ. Failure of the fontan circulation. Heart Fail Clin. 10(1):105-116 (January 2014); Egbe AC, Connolly HM, Miranda WR, Ammash NM, Hagler DJ, Veldtman GR and Borlaug BA. Hemodynamics of Fontan Failure: The Role of Pulmonary Vascular Disease. Circ Heart Fail. 10(12):e004515 (September 2017); and Gewillig M, Brown SC, Eyskens B, Heying R, Ganame J, Budts W, La Gerche A and Gorenflo M. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg.10(3):428-433(March 2010). There are many basic limitations to the efficiency of the Fontan circulation, usually including abnormal pulmonary vascular resistance, single ventricular diastolic function, systemic and pulmonary endothelial dysfunction, pathological vascular remodeling, etc. Egbe AC, Connolly HM, Miranda WR, Ammash NM, Hagler DJ, Veldtman GR and Borlaug BA. Hemodynamics of Fontan Failure: The Role of Pulmonary Vascular Disease. Circ Heart Fail.10(12):e004515(September 2017); Averin K, Hirsch R, Seckeler MD, Whiteside W, Beekman RH, 3rd and Goldstein BH. Diagnosis of occult diastolic dysfunctionlate after the Fontan procedure using a rapid volume expansion technique. Heart.102(14):1109-1114(July 15, 2016)Goldstein BH,Connor CE,Gooding Land Rocchini AP.Am J. Relationship of systemic venous return, pulmonaryvascular resistance, and diastolic dysfunction to exercise capacity in patients with single ventricle receiving fontan palliation Cardiol.105(8):1169-1175(April 15, 2010):Hays BS,Baker M,Laib A,Tan W,Udholm S,GoldsteinBH,Sanders SP,Opotowsky AR and Veldtman GR subjects.Heart.104(4):324-331(February 2018):Khambadkone S,Li J,de Leval MR,Cullen S,Deanfield JE and RedingtonAN.Basal pulmonary vascular resistance and nitric oxide responsiveness late after the Fontan type operation.Circulation.107(25):3204-3208(July 1, 2003):Mitchell MB,Campbell DN,Ivy D,Boucek MM,Sondheimer HM,Pietra B,Das BB andColl JR Cardiovasc Surg.128(5):693-702(11 / 2004) and Sarkola T,Jaeggi E,Slorach C,Hui W,Bradley T andRedingtonAN.Assessment of vascular remodeling after the Fontan procedure using a novel very high resolution ultrasound method: arterial wall thinning and venous thickening in late follow-up. Heart Vessels. 28(1):66-75 (January 2013). .
[0335] Although each pathological feature of the circulation may represent a potential therapeutic target, pharmacological therapy with agents designed to reduce pulmonary vascular resistance makes intuitive sense given its broad tolerability, its efficacy in treating pulmonary hypertension, and its unique role as a regulator of cardiac output after Fontan. Egbe AC, Connolly HM, Miranda WR, Ammash NM, Hagler DJ, Veldtman GR and Borlaug BA. Hemodynamics of Fontan Failure: The Role of Pulmonary Vascular Disease. Circ Heart Fail. 10(12):e004515 (September 2017).
[0336] Previous studies of the use of other pulmonary vasodilators in those patients with Fontan circulation have been equivocal. Agnoletti G, Gala S, Ferroni F, Bordese R, Appendini L, Pace Napoleone C and Bergamasco L. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation. J ThoracCardiovasc Surg. 153(6):1468-1475 (June 2017); Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wemovsky G, Paridon SM and Rychik J. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossovertrial. Circulation.123(11):1185-1193 (May 22, 2011); Hebert A, Mikkelsen UR,Thilen U,Idom L,Jensen AS,Nagy E,Hanseus K,Sorensen KE and SondergaardL.Bosentan improves exercise capacity in adolescents and adults after Fontanoperation:the TEMPO(Treatment With Endothelin Receptor Antagonist in FontanPatients,a Randomized,Placebo-Controlled,Double-Blind Study Measuring PeakOxygen Consumption)study.Circulation.130(23):2021-2030(12 / 2 / 2014);Mori H,Park IS,Yamagishi H,Nakamura M,Ishikawa S,Takigiku K,Yasukochi S,Nakayama T,Saji T and Nakanishi T.Sildenafil reduces pulmonary vascular resistance single ventricular physiology.Int JCardiol.221:122-127(October 15, 2016):RhodesJ,Ubeda-Tikkanen A,Clair M,Fernandes SM,Graham DA,Milliren CE,Daly KP,MullenMP and Landzberg MJ.Effect of inhaled iloprost on the exercise function ofFontan patients:a demonstration of concept.Int J Cardiol.168(3):2435-2440(October 3, 2013);Schuering MJ,Vis JC,van Dijk AP,van Melle JP,Vliegen HW,Pieper PG,Sieswerda GT,deBruin-Bon RH,Mulder BJ and Bouma BJ.Impact ofbosentan on exercise Eur J Heart Fail.15(6):690-698(June 2013);TunksRD,Barker PC,Benjamin DK,Jr,Cohen-Wolkowiez M,Fleming GA,Laughon M,Li JS andHill KD.Sildenafil exposure and hemodynamic effect after fountain surgery.Pediatr Crit Care Med.15(1):28-34(January 2014); Van De Bruaene A, LaGerche A, Claessen G, De Meester P, Devroe S, Gillijns H, Bogaert J, Claus P, Heidbuchel H, Gewillig M and Budts W. Sildenafil improves exercise hemodynamics in Fontan patients. Circ Cardiovasc Imaging.7(2):265-273 (March 2014); GoldbergDJ, French B, Szwast AL, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wemovsky G, Paridon SM and Rychik J. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Pediatr Cardiol. 33(5):689-696 (June 2012); and Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M and Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 29(13):1681-1687 (July 2008). Some small single-site studies in a range of pulmonary vasodilator classes have shown acute improvement after a single dose, but these studies did not look at sustained effect or long-term use. Rhodes J, Ubeda-Tikkanen A, Clair M, Fernandes SM, Graham DA, Milliren CE, Daly KP, Mullen MP and Landzberg MJ. Effect of inhalediloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol.168(3):2435-2440 (October 3, 2013); Tunks RD, Barker PC, Benjamin DK, Jr., Cohen-Wolkowiez M, Fleming GA, Laughon M, Li JS and HillKD. Sildenafil exposure and hemodynamic effect after Fontan surgery. PediatrCrit Care Med.15(1):28-34(January 2014); Van De Bruaene A, La Gerche A, Claessen G, De Meester P, Devroe S, Gillijns H, Bogaert J, Claus P, Heidbuchel H, Gewillig Mand Budts W. Sildenafil improves exercise hemodynamics in Fontan patients. CircCardiovasc Imaging.7(2):265-273 (March 2014); and Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M and Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 29(13): 1681-1687 (July 2008). Two moderately sized studies have evaluated the use of endothelin receptor antagonists in adolescents and adults after Fontan, but the two trials showed conflicting results and no phase I testing was performed in this cohort. Hebert A, Mikkelsen UR, Thilen U, Idom L, Jensen AS, Nagy E, Hanseus K, Sorensen KE and Sondergaard L.Bosentan improves exercise capacity inadolescents and adults after Fontan operation:the TEMPO(Treatment WithEndothelin Receptor Antagonist in Fontan Patients,a Randomized,Placebo-Controlled,Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation. 130(23):2021-2030 (December 2, 2014); and Schuuring MJ, Vis JC, vanDijk AP, van Melle JP, Vliegen HW, Pieper PG, Sieswerda GT, de Bruin-Bon RH, MulderBJ and Bouma BJ. Impact of bosentan on exercise capacity in adults after theFontan procedure: arandomized controlled trial. Eur J Heart Fail. 15(6):690-698 (June 2013). Furthermore, in this study that suggested a benefit, the benefit was associated with a decrease in hemoglobin levels, a side effect that could offset the drug's supposed benefit. Hebert A, Mikkelsen UR, Thilen U, Idom L, Jensen AS, Nagy E, Hanseus K, Sorensen KE and Sondergaard L. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double Blind Study Measuring Peak Oxygen Consumption) study. Circulation.130(23):2021-2030 (December 2, 2014). The FUEL trial is the first large-scale, multi-institutional study to demonstrate physiological benefits associated with the use of a specific pulmonary vasodilator at a dose established in a phase I clinical trial after Fontan palliation in adolescents with SVHD.
[0337] Assessments of athletic performance well demonstrate the challenges of living with Fontan physiology. Compared with healthy peers, adolescents with Fontan physiology have reduced athletic ability, a difference that worsens over time and is associated with increased hospitalizations and heart failure symptoms. Fernandes SM, McElhinney DB, Khairy P, Graham DA, Landzberg MJ and Rhodes J. Serial cardiopulmonary exercise testing inpatients with previous Fontan surgery. Pediatr Cardiol. 31(2):175-180 (February 2010); Giardini A, Hager A, Pace Napoleone C and Picchio FM. Natural history of exercise capacity after the Fontan operation: a longitudinal study. Ann ThoracSurg.85(3):818-21(March 2008); Jenkins PC, Chinnock RE, Jenkins KJ, Mahle WT, MullaN, Sharkey AM and Flanagan MF. Decreased exercise performance with age inchildren with hypoplastic left heart syndrome.J Pediatr.152(4):507-512(April 2008); Paridon SM, Mitchell PD, Colan SD, Williams RV, Blaufox A, Li JS, MargossianR, Mital S, Russell J, Rhodes J and Pediatric Heart Network IA cross-sectional study of exercise performance during the first 2decades of life after the Fontan operation. J Am Coll Cardiol.52(2):99-107(July 8, 2008)Atz AM,Zak V,Mahony L,Uzark K,D'Agincourt N,Goldberg DJ,Williams RV,Breitbart RE,Colan SD,Burns KM,Margossian R,Henderson HT,Korsin R,Marino BS,Daniels J Am Coll Cardiol.69(22):2735-2744(June 6, 2017);Diller GP,Dimopoulos K,Okonko D,Li W,Babu-Narayan SV,Broberg CS,Johansson B,Bouzas B,Mullen MJ,Poole-Wilson PA,Francis DP and GatzoulisMA.Exercise intolerance in adult congenital heart disease:comparativeseverity,correlates,and prognostic implication.Circulation.112(6):828-35(August 9, 2005);Diller GP,Giardini A,Dimopoulos K,Gargiulo G,Muller J,Derrick G,Giannakoulas G,Khambadkone S,Lammers AE,Picchio FM,Gatzoulis MAand HagerA.Predictors of Morbidity and mortality in contemporary Fontan patients:results from a multicenter study including cardiopulmonary exercise testingin 321patients.Eur Heart J. 2013-2014.31(24):3073-3083 (December 2010); Cunningham JW, Nathan AS, Rhodes J, Shafer K, Landzberg MJ and Opotowsky AR. Decline in peak oxygen consumption over time predicts death or transplantation in adults with a Fontan circulation. Am Heart J. 189:184-192 (July 2017); and Udholm S, Aldweib N, Hjortdal VE and Veldtman GR. Prognostic power of cardiopulmonary exercise testing in Fontan patients: a systematic review. Open Heart. 5(1):e000812 (July 2018). Exercise capacity less than 50% of that predicted for age and sex is the approximate threshold above which circulatory-related diseases become common, usually occurring during the third decade of life but may occur earlier. Diller GP, Giardini A, Dimopoulos K, Gargiulo G, Muller J, Derrick G, Giannakoulas G, Khambadkone S, Lammers AE, Picchio FM, Gatzoulis MAand Hager A. Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients. Eur Heart J. 31(24):3073-3083 (December 2010). The ability to improve exercise capacity, as a marker of improved circulatory function more generally, may be critical to the long-term health of those patients undergoing Fontan surgery. This trial suggests that udenafil may help improve key measures of exercise capacity in Fontan patients following pharmacological intervention. .
[0338] The FUEL trial had the power to detect changes in peak VO2 because peak VO2 is relatively easy to measure and has been used as an accepted surrogate for cardiac events in previous trials. Dallaire F,Wald RM and MarelliA.The Role of Cardiopulmonary Exercise Testing for Decision Making inPatients with Repaired Tetralogy of Fallot.Pediatr Cardiol.38(6):1097-1105(August 2017); Mancini D,LeJemtel T and Aaronson K.Peak VO(2):a simple yetenduring standard.Circulation.101(10):1080-1082(March 2000);Okonko DO,GrzesloA,Witkowski T,Mandal AK,Slater RM,Roughton M,Foldes G,Thum T,Majda J,BanasiakW,Missouris CG,Poole-Wilson PA,Anker SD and Ponikowski P.Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemicpatients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol.51(2):103-112 (January 15, 2008); and Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, GivertzMM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E and Trial R. Effect of phosphodiesterase-5inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.JAMA.309(12):1268-1277 (March 27, 2013). However, although peak VO2 can be used as a surrogate for many cardiovascular disease states, it may not be a relevant endpoint after Fontan surgery. In this unique physiology, central venous pressure rather than right ventricular contraction is the primary driver of transpulmonary blood flow and, therefore, cardiac output. Gewillig M and Goldberg DJ. Failure of the fontan circulation. Heart Fail Clin. 10(1):105-116 (January 2014); Egbe AC, Connolly HM, Miranda WR, Ammash NM, Hagler DJ, Veldtman GR and'Borlaug BA. Hemodynamics of Fontan Failure: The Role of Pulmonary VascularDisease. Circ Heart Fail.10(12):e004515 (September 2017); Gewillig M, Brown SC, Eyskens B, Heying R, Ganame J, Budts W, La Gerche A and Gorenflo M.The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg. 10 (3): 428-433 (March 2010); and Goldberg DJ, Avitabile CM, McBride MG and Paridon SM. Exercise capacity in the Fontan circulation. Cardiol Young. 23 (6): 824-830 (December 2013). As the demand for cardiac output increases with exertion, the central venous pressure in the Fontan circulation must rise to meet this demand, but eventually reaches a critical upper limit, beyond which it will no longer rise further. Navaratnam D, Fitzsimmons S, Grocott M, Rossiter HB, Emmanuel Y, Diller GP, Gordon-Walker T, Jack S, Sheron N, Pappachan J, Pratap JN, Vettukattil JJ and Veldtman G. Exercise-Induced Systemic Venous Hypertension in the Fontan Circulation. Am J Cardiol. 117(10):1667-1671 (March 15, 2016). During submaximal exertion, the increase in central venous pressure does not reach the physiological upper limit, so the results of exercise at this level may be more sensitive to pharmacological manipulation of the pulmonary vasculature. This is evidenced by the relatively high ratio of oxygen consumption and work done at anaerobic threshold compared with peak exercise, which is different from the physiology of patients with submaximal exercise, in which central venous pressure changes little during exercise and the trend of improvement or decline in VO2 and peak VO2 at VAT is generally equal. .
[0339] Despite the importance of the findings reported in this article, the trial has limitations. First, to minimize burden on participants, the study design did not include detailed hemodynamic measurements, such as those that might be obtained with cardiac magnetic resonance imaging or invasive catheterization studies. In addition, evaluation of PAT outcomes did not reveal a benefit of udena over placebo. [? ] Further interrogation of the multiple measurements provided by these studies was not performed in this primary analysis but will be the subject of future analyses. Finally, the duration of the FUEL trial precludes long-term assessment of safety, although this issue is being addressed in the ongoing FUEL open-label extension study.
[0340] Treatment with udenafil (87.5 mg twice daily) in addition to standard therapy was not associated with statistically significant improvements in oxygen consumption at peak exercise but did show statistically significant improvements in multiple measures of exercise performance at the ventilatory anaerobic threshold. As the first large, multicenter, placebo-controlled, randomized trial to demonstrate measurable physiological benefits in Fontan patients, the FUEL trial represents a milestone in the nearly 50 years of experience with the Fontan cycle and serves as an example of how public-private collaboration can advance the science of congenital heart disease. Further studies are warranted to determine whether udenafil selectively benefits subpopulations within a larger cohort of patients with SVHD and to assess the long-term tolerability and safety of treatment.
[0341] The entire contents of the disclosures cited in this Example 2 are incorporated herein by reference as if fully set forth herein.
[0342] Example 3
[0343] Udenafil tablets preparation
[0344] An exemplary formulation of a tablet containing 87.5 mg of Udenafil is detailed in Table 11. The Udenafil formulation reported in Table 11 was used in Fontan patients enrolled in the FUEL trial discussed in Examples 1 and 2 above.
[0345] Table 11: Composition of 87.5 mg Udenafil tablets.
[0346]
[0347] 1 Purified water (USP) is removed during the manufacturing process and is not part of the final dosage form.
[0348] 2 Based on nominal coating weight gain 3.2% w / w.
[0349] 3 Opadry White contains hypromellose, hydroxypropyl cellulose, titanium dioxide, and polyethylene glycol.
[0350] Example 4
[0351] Effects of udenafil on echocardiographic parameters of myocardial performance in patients with SVHD undergoing Fontan palliative therapy
[0352] The purpose of the FUEL trial was to determine the effects of udenafil on echocardiographic measures of myocardial performance in adolescents aged approximately 12 to 18 years with functional single ventricle physiology after the Fontan procedure. The FUEL trial was a randomized, double-blind, placebo-controlled trial and was conducted at 30 different sites in the United States (26), Canada (2), and South Korea (2) in adolescents aged approximately 12 to 18 years after the Fontan procedure. Fontan patients were randomly assigned to receive either placebo or udenafil (87.5 mg twice daily) for 26 weeks.
[0353] Each subject underwent echocardiography at baseline and at the end of 26 weeks. Paired echocardiographic data for MPI measurements were available for 250 subjects (63%); 122 in the udenafil group and 128 in the placebo group. Table 3. There was a statistically significant change in MPI in the udenafil-treated group (-0.02 decrease, improvement) compared with the placebo group (+0.01 increase, no improvement) (p = 0.028). The change in MPI was determined by velocities obtained from blood pool Doppler assessment of the inflow and outflow tracts of a single functioning, normally dominant ventricle. All measurements were performed by the Children's Hospital of Wisconsin Echocardiography Core Laboratory. Over the same time period, subjects treated with udenafil demonstrated a statistically significant improvement in the myocardial performance index (MPI) compared with subjects taking placebo (decrease indicating improvement), p = 0.028.
[0354] These data show that MPI improved in the udenafil group relative to the placebo group (-0.02 vs +0.01, p = 0.028). Myocardial performance is an important factor in the long-term health of SVHD patients, including those who have undergone the Fontan procedure, and improvements in this aspect of physiology complement improvements in motor performance, suggesting that the benefits of treatment with udenafil may be multifactorial.
[0355] All disclosures, including all patents, patent documents, articles, abstracts, errata, and publications referenced or cited herein, including U.S. patent application serial number 14 / 788,211, U.S. Patent Publication No. 2019 / 0030037, U.S. Patent No. 10,137,128, and U.S. patent application serial number 15 / 887,523, U.S. Patent Publication No. 2018 / 0169103, U.S. Patent No. 10,653,698, Goldberg, DJ et al.: Results of the FUEL Trial. Circulation. 141:641-651 (February 25, 2020) and Goldberg, DJ et al.: Correction to: Results of the FUEL Trial. Circulation. 142:e31 (July 14, 2020), are incorporated herein by reference in their entirety, as if each article was individually incorporated herein in its entirety.
[0356] In the event of a conflict with other related, earlier-filed applications cited in "Related Applications", this specification (including definitions) shall control.
[0357] It will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope and spirit of the present invention. The illustrative embodiments and examples are provided as examples only and are not intended to limit the scope of the present invention. The scope of the present invention is limited only by the appended claims.
[0358] Example 5
[0359] This Example 5 demonstrates the efficacy of Udenafil in the sub-super Fontan population with a baseline peak or maximum VO2 < 80% of the predicted value, the secondary efficacy of Udenafil in sub-super Fontan patients and super Fontan patients, the importance of VO2 under VAT in all Fontan patients (including super Fontan patients and sub-super Fontan population with a baseline peak VO2 ≥ 80% of the predicted value), and the FUEL OLE trial confirms the clinical benefits of treating Fontan patients with Udenafil.
[0360] (a) Peak VO2 in sub-super-Fontan patients with a baseline predicted peak VO2 percentage < 80%
[0361] The following demonstrates that the Fontan population with baseline peak VO2 < 80% predicted, which represents 75% of the total FUEL trial enrollment population, is an appropriate population to analyze the effects of udenafil medication in improving exercise capacity at peak exercise in Fontan patients, an orphan, pediatric population with serious and life-threatening unmet needs.
[0362] At the time the FUEL trial began, the scientific community had not yet identified a subset of the Fontan population, the so-called “super-Fontan” patients, who were able to achieve peak exercise levels at or near normal levels for those with a biventricular (normal) heart. It was not until June 2018, as the FUEL trial was nearing completion of enrollment, that the concept of a “super-Fontan”—defined as having a peak VO2 ≥ 80% predicted—began to appear in the medical literature. See Cordina 2018, Powell 2019, and Weinrab 2020. The relevance or even existence of this super-Fontan subset was largely unknown during the clinical trial design of the FUEL trial and could not have been anticipated when the FUEL trial was designed and submitted for FDA review and consent.
[0363] As super-Fontan patients have become recognized, so has the understanding of the physiological upper limit to peak exercise in the Fontan cycle. When super-Fontan patients reach peak levels of exercise, central venous pressure, the driver of cardiac output, is already close to maximal physiological values and cannot be meaningfully increased further. (Goldberg 2021) and (Navaratnam 2016). This physiological upper limit to central venous pressure is believed to limit the ability to further increase peak exercise in this population. However, despite this limited ability to improve peak exercise, enhancements in exercise at the ventilatory anaerobic threshold (“VAT”) have been unexpectedly achieved in super-Fontan patients, as the ventilatory anaerobic threshold is believed to occur below the physiological upper limit of central venous pressure.
[0364] Based on the clinical rationale for this subgroup analysis described above, the response of individual subjects to treatment with udenafil depends in part on their peak or maximal exercise capacity at trial entry. An analysis of covariance was performed with fixed factors for treatment group (udenafil vs placebo), baseline peak exercise capacity subset (predicted peak VO2 percentage <80% vs ≥80% subgroup; a cut point defined in the Fontan medical literature), and treatment group by subset interaction. The analysis was performed on peak or maximal VO2 and exercise measures at the ventilatory anaerobic threshold ("VAT") and the myocardial performance index (MPI). The results are shown in Table 1.
[0365]
[0366] VO2: oxygen consumption; VAT: ventilatory anaerobic threshold; VE / VCO2: ventilatory efficiency slope; MPI: myocardial performance index.
[0367] #Analysis based on natural log-transformed data. Mean % change from baseline ratio for udenafil / placebo.
[0368] **p-values for treatment group (udenafil, placebo), subset (<80% predicted baseline peak VO2≥80%), and treatment group-subset interaction term in the linear model.
[0369] The interaction term tested the assumption of homogeneity of treatment effect (udenafil-placebo) between the two subsets (<80% vs. ≥80%).
[0370] The p-value reflects the likelihood of observing different treatment effects between the two subsets, assuming that the treatment effects in the two subsets are equal.
[0371] ANCOVA analysis with fixed factors confirmed a significant interaction between treatment group and baseline peak exercise capacity subset for the outcome measure of peak VO2 (p=0.037), but no significant interaction between treatment group and subset for the outcomes of exercise at ventilatory anaerobic threshold (all p≥0.58) and MPI (p=0.17). These results are believed to confirm that baseline peak exercise capacity has a significant effect on the drug treatment effect of peak or maximum VO2, while baseline exercise capacity has no significant effect on the drug treatment effect of other (secondary) outcome measures. Taken together, these results support the new understanding of Fontan physiology first published in the medical literature in 2018 and reveal that, in particular, the inclusion of Fontan patients with a baseline predicted peak VO2 percentage ≥80% had a deleterious effect on the primary outcome of peak or maximum VO2 in the FUEL trial (e.g., the de-enriched trial cohort).
[0372] (b) Evidence of clinical efficacy.
[0373] In the FUEL trial, the p-value for the improvement in the primary outcome measure, peak VO2, was 0.092—a statistically near miss, but still significant. Given the new scientific knowledge about Fontan physiology since the design of the FUEL trial (e.g., “super-Fontan” and ceiling effects), and the confirmation of this knowledge by the above analysis, the effect of udenafil was statistically significant in sub-super-Fontan patients with a baseline predicted peak VO2 percentage of <80%. In fact, if the new medical knowledge had been available during the design of the trial, the analysis captured the exact population that was prospectively studied in FUEL (e.g., the trial exclusion criteria of increasing baseline peak VO2 ≥80%). Importantly, this subgroup analysis included Fontan patients with decreased peak exercise performance, who are precisely the population at greatest risk for near-term adverse outcomes, including death, transplantation, or hospitalization for heart failure (Udholm 2018; Giardini 2007; Diller 2010: Femandes 2011, Ohuchi 2015). It should be noted that the total sample size for this subgroup analysis was n=301.
[0374] As shown in Table 2, subgroup analysis of those with a baseline predicted peak VO2 percentage < 80% demonstrated significant improvement in peak or maximum VO2. This improvement in peak or maximum VO2 was consistent with statistically significant improvements in all secondary outcome measures in the ITT cohort and subgroup analyses, including exercise under VAT and MPI, the primary outcome of ventricular performance. Based on the new analysis described above, these submaximal findings were expected; improvements under VAT were found regardless of baseline peak exercise capacity (e.g., even when "super Fontan" patients were included in the ITT cohort).
[0375]
[0376]
[0377] While the benefit of udenafil was clear in sub-super-Fontan patients with a peak or max VO2 <80% predicted at baseline, the results appeared to be negative in super-Fontan patients with a peak or max VO2 ≥80% predicted. In fact, in this small subgroup (n=77), the 26-week change in peak or max VO2 did not reveal a significant udenafil treatment effect (Table 1; p=0.32). The emergence of a slightly negative treatment effect of udenafil in this super-Fontan subgroup was not statistically significant, which in part reflects the small sample size and would not have been expected to become significant even with adequate power, given that all secondary exercise measures showed a positive udenafil treatment effect in the entire study population. This discussion will be discussed below in conjunction with the Figure 6Continue in the relevant chapter.
[0378] (c) Clinical significance of the udenafil treatment effect in the intention-to-treat analysis and post hoc subgroup analysis of patients with baseline peak VO2 < 80% predicted.
[0379] There is recent literature (Cunningham, 2017 and Egbe, 2017) linking changes in exercise performance (peak VO2, mL / kg / min) to short- and medium-term risk of death and heart transplantation in Fontan patients. The studies by Cunningham and Egbe strongly support that the FUEL results (peak VO2, mL / kg / min) are highly clinically significant, unexpected, and relevant.
[0380] (1) Clinical significance: Changes in peak VO2 in the Fontan population (mL / kg / min)
[0381] In a 2017 study from Boston Children's Hospital, Cunningham and colleagues investigated the effects of changes in peak VO2 on short-term clinical outcomes in 130 adolescent and young adult Fontan patients (mean age 26.8 ± 9.4 years) with paired cardiopulmonary exercise testing (CPET) studies separated by 1.4 ± 0.5 years. When change in peak VO2 was assessed as a continuous variable, higher peak VO2 (mL / kg / min) at the second CPET was significantly associated with a reduced short-term risk of death or transplantation. Specifically, an increase in peak VO2 of 1 ml / kg / min was associated with a HR of 0.79 (95% CI 0.68-0.92, p = 0.004) for death or transplantation. Furthermore, for every 10% decrease in peak VO2, the risk of death or transplantation doubled (HR 1.96, 95% CI 1.2-3.1, p = 0.004). When peak VO2 was assessed as a dichotomous outcome (e.g. Figure 8 Any decrease in peak VO2 was associated with a significant increase in the short-term risk of: a) death or transplantation (p=0.027); b) death, transplantation, or hospitalization for heart failure (p=0.024); and c) a near-significant risk of death, transplantation, or non-elective cardiovascular hospitalization (p=0.14).
[0382] In addition, Cunningham (2017) evaluated the performance of CPET stratified by the subsequent primary clinical outcome of death or transplantation. Fig. 9Fontan survivors (grey) showed increases in percent predicted peak VO2 (left) and percent change in peak VO2 (right) between CPET studies, whereas Fontan patients who subsequently achieved the primary clinical outcome (black) showed decreases in both exercise measures.
[0383] Egbe et al (2017) investigated the prognostic value of serial CPET testing in young adults who had previously undergone Fontan surgery. In this important study from the Mayo Clinic, 145 Fontan patients with a mean age of 24 ± 3 years were included, and CPET studies performed at intervals of 3.8 ± 0.3 years were evaluated. During the interim follow-up of 8 ± 3 years, 37% of the patients had experienced adverse cardiovascular events. Many risk factors for adverse cardiovascular events were considered. Fig.10 Freedom from adverse cardiovascular events is depicted, stratified by percent annual decline in predicted peak VO2 ≥3% (blue) or <3% (red). The only predictor of 5-year risk of adverse cardiovascular events was a ≥3% annual decline in predicted peak VO2 (p=0.03).
[0384] In the intention-to-treat analysis (ITT) of the FUEL trial, Fig.11 Without imputing missing data, 46% (n=86) of udenafil patients showed an increase in peak VO2, whereas only 36% (n=68) of placebo patients had an increase in peak VO2. This difference was barely statistically significant (p=0.075) and corresponds to a number needed to treat (NNT) of 10, meaning that 10 patients would need to be treated with udenafil for one patient to experience an increase in peak VO2. Alternatively, in the context of the outcome data provided by the Cunningham study, an NNT of 10 would mean that 10 patients would need to be treated with udenafil for one patient to show a substantial reduction in the short-term risk of death or transplantation.
[0385] In a post hoc subgroup analysis of the FUEL trial (excluding patients with baseline peak VO2 ≥ 80% predicted), Fig.12 , 50% (n=75) of the udenafil patients showed an increase in peak VO2, while only 38% (n=57) of the placebo patients had an increase in peak VO2. This difference was statistically significant (p=0.037) and corresponded to a number needed to treat (NNT) of 8.2, meaning that approximately 8 patients would need to be treated with udenafil for one patient to show an increase in peak VO2. Considering the outcome data of Cunningham et al., approximately 8 patients would need to be treated with udenafil for one patient to show a substantial reduction in the short-term risk of death or transplantation.
[0386] Given concerns about a possible negative treatment effect of udenafil in the super-Fontan cohort at a post-cycle conference, this same analysis was performed post hoc in a subgroup of patients with baseline peak VO2 ≥ 80% predicted in the FUEL trial. Fig.13 . We found that the percentage of patients who were equally low in each treatment group (28% to 29%) showed positive changes, while the percentage of patients who were equally high in each treatment group (71% to 72%) showed negative changes, with no differences between treatment groups (p>0.99). These findings are consistent with the results of the ANCOVA with fixed effects analysis, whereby there was a significant interaction between baseline peak VO2 subgroup and treatment group (e.g., high baseline exercise capacity precluded further benefit of the drug). More importantly, it is important to recognize that in this super-Fontan subgroup, udenafil treatment did not appear to have a significant short-term effect (beneficial or adverse) on the outcome measure of peak VO2.
[0387] Next, we show the percent change in peak VO2 during the 26-week FUEL trial for the ITT cohort (left) and post hoc subgroups (excluding patients with baseline peak VO2 ≥ 80% predicted, right). Fig.14 . In the ITT analysis, both groups showed a negative percentage change in peak VO2, although to a much lesser extent in the udenafil group, with no statistical difference between the groups (p = 0.072). However, in a post hoc subgroup analysis, the mean effect on peak VO2 was positive in the udenafil group, whereas the placebo group again showed a worsening. This difference was statistically significant (p = 0.037). Given the study risks of Cunningham, our data predict that udenafil should be associated with a reduction in the short-term risk of death or transplantation for Fontan patients in a post hoc subgroup analysis.
[0388] Now, the annual change in predicted peak VO2 percentage is shown, Fig.15; (determined by doubling the change within the 6-month FUEL trial), ITT cohort (left) and post hoc subgroups (excluding patients with baseline peak VO2 ≥ 80% predicted, right). Annualizing the 6-month change in FUEL facilitates direct comparison with Egbe's Fontan cohort. In the ITT analysis, both groups showed a decrease in percent predicted peak VO2, although only the placebo group exceeded Egbe et al.'s threshold of a 3% annual decrease associated with an increased 5-year risk of adverse cardiovascular events. This difference was not statistically significant (p = 0.077). However, in a post hoc subgroup analysis, the udenafil group showed an increase in percent predicted peak VO2, while the placebo group again showed a decrease. This difference was statistically significant (p = 0.009). Furthermore, only the placebo group exceeded the threshold of a 3% annual decrease associated with an increased 5-year risk of adverse cardiovascular events (Egbe 2017).
[0389] Finally, in the absence of existing pharmacological therapies for the treatment of SVHD patients following Fontan palliation, it would be prudent to compare the treatment effects in FUEL with non-pharmacological treatment options aimed at improving exercise capacity in this population. Few, but exercise training or cardiac rehabilitation are the most plausible non-pharmacological therapies with an available evidence base for review. Scheffers et al (2021) recently conducted a systematic review of 16 studies reported in 22 publications that included 264 Fontan patients with a mean age range of 8.7–31 years. In this systematic review, the authors reported a significant increase in peak VO2 following training in only 9 studies (5.6%), with a mean increase of +1.72 ml / kg / min in those studies that demonstrated a benefit. Of note, this reported increase does not reflect a placebo-adjusted treatment effect, but rather simply the average increase in patients who underwent exercise training. However, when all studies were included in the calculation of change in peak VO2, such as Fig.16 As shown, the mean increase was only slightly greater than 0 ml / kg / min. Given the ongoing controversy surrounding physical training as a treatment to maintain or improve exercise capacity in Fontan patients, the Fontan Fitness Intervention Trial (F-FIT), a randomized, multicenter controlled study in adolescent and adult Fontan patients, is currently underway in Australia (Tran 2022).
[0390] This review of recent and relevant Fontan literature relates changes in exercise performance (peak VO2, mL / kg / min) to short- to medium-term risks of adverse clinical outcomes, including death and cardiac transplantation, which are relevant to the interpretation of the results of the primary and post hoc subgroup analyses of the FUEL trial. These data and analyses strongly support that the FUEL results (peak VO2, mL / kg / min) are highly clinically significant, unexpected, and relevant. Furthermore, in the absence of available medical therapies indicated for Fontan cycle treatment, alternative treatments must be weighed. Physical training (cardiac rehabilitation) has been repeatedly tried in the Fontan population, with benefits evident only about half the time and overall effects on peak VO2 being negligible across the entire analysis cohort. Finally, the short-term nature of these risks, including death and transplantation, suggests that there is a real need for effective treatment options in the Fontan population. Every year of delay in obtaining effective treatment options will inevitably result in a significant number of Fontan patients dying from ongoing mortality or compromised cardiac transplantation.
[0391] (d) The importance of VO2 under VAT in the clinical management of the Fontan population (including super-Fontan patients).
[0392] Peak VO2 is an important marker of overall cardiovascular health and a predictor of adverse cardiac events, but it is not often achieved in patients' daily lives. On the other hand, VO2 at VAT is the upper limit of sustained physical activity and sets the limit on how regular physical activity an individual patient can perform. This measurement is the point during progressive physical activity when the metabolic demands of the exercising muscles exceed the ability of the cardiovascular system to maintain adequate blood flow to deliver oxygen, so metabolism switches from aerobic to anaerobic. In healthy adolescents and children, this point typically occurs at approximately 55% to 60% of the subject's maximum VO2 and is the limit of physical activity that can be maintained indefinitely. In the FUEL trial, treatment with udenafil resulted in a robust increase in VO2 at VAT compared with placebo in the overall intention-to-treat population as well as in the super-Fontan patient analysis.
[0393] The clinical relevance of this finding is very important. Individuals rarely, if ever, move at anything close to their VO2max during daily activities. Therefore, although peak VO2 is an important marker of overall cardiovascular health and a good predictor of adverse cardiovascular events, it has limited impact on how patients feel or function in their daily lives. On the other hand, VO2 at VAT sets limits on how much activity an individual patient must be able to perform on a daily basis. These limits determine the ability to perform daily activities, including work, school, and recreation. Any improvement in VO2 at VAT will necessarily lead to improved tolerability of these regular activities.
[0394] Although VO2 under VAT is a highly clinically relevant endpoint, it can be challenging to obtain. In order to accurately and precisely measure VAT, respiratory rate and tidal volume must be consistent. In clinical practice, erratic breathing at the onset of anaerobic metabolism prevents accurate assessment of approximately 15% to 20% of exercise tests performed. This measurement difficulty is of particular concern when designing clinical trials with VO2 under VAT as an endpoint, as sample size calculations must be expanded to account for expected data loss. Given concerns about data availability, and the knowledge that recruiting participants in this orphan disease space would be a challenge, the Pediatric Heart Network elected to use VO2 under VAT as a secondary endpoint. However, although paired VAT data were available in approximately 80% of the cohort, as expected, this measure demonstrated a clinically and statistically significant response in the entire population.
[0395] The importance of VO2 under VAT as an endpoint was highlighted in a 2007 report by McCrindle et al. (McCrindle 2007) in which they investigated the relationship between parent / patient perceptions of functional health and measures of exercise performance in 147 Fontan patients with a median age of 11.6 years (range 7–18.4 years). In this cohort, the mean percentage of predicted peak VO2 was 67% ± 15%, which is directly comparable to the performance of the FUEL cohort. The authors found that greater exercise capacity was associated with higher scores on overall health, physical function, impact of physical limitations, absence of bodily pain, general health perception, and summary of physical function (p < 0.05 for each item). In fact, for several key measures of functional status, including overall health, physical function, impact of physical limitations, and self-esteem, percentage of predicted VO2 under VAT was more strongly correlated with measures of exercise capacity than peak VO2. Given the clinical correlations between percent predicted VO2 at VAT and overall health (R 0.45, p < 0.05) and self-esteem (R 0.28, p < 0.05), even modest drug effects would be expected to produce perceptible functional benefits for patients and parents. Fig.17 As shown in Figure 2, more patients experienced a positive change in VO2 under VAT when treated with udenafil compared with placebo, although this difference was not statistically significant (p = 0.311). Fig.18As shown, udenafil treatment resulted in substantially better preservation of VO2 under VAT compared with placebo in both the ITT cohort as a whole (p=0.026) and in a subgroup analysis excluding super-Fontan patients (p=0.052). In the context of the McCrindle data, this suggests that udenafil therapy is associated with better maintenance of existing functional status compared with the inevitable decline in functional status experienced with non-therapy (such as placebo or Fontan natural history). These findings support the view that udenafil-mediated improvements in VO2 under VAT, in addition to improvements in peak VO2, are associated with clinically significant improvements in multiple domains of functional health status.
[0396] (e) Confirmation of clinical benefit in the Fontan population from the FUEL OLE (open-label extension) trial
[0397] To confirm the benefit of udenafil demonstrated in FUEL, we evaluated available clinical data from participants in the FUEL OLE trial. Like most extension studies, the FUEL open-label extension trial was not a placebo-controlled trial but was designed to establish safety over a longer duration of drug exposure and was an independent source of data from FUEL. Despite the inherent limitations of this extension study, FUEL OLE provided supportive evidence for the efficacy of udenafil, as follows Fig.19 The results are depicted in the 18 months of FUEL and FUEL OLE. The benefit persisted in those patients treated with udenafil in the FUEL trial, and for those patients who had not been treated with udenafil, there was a new benefit in the FUEL trial that recapitulated that observed relative to placebo. In the OLE study, all patient groups demonstrated substantial clinical benefit from udenafil treatment from 26 to 78 weeks.
[0398] The FUEL and FUEL OLE trials have unexpectedly and surprisingly demonstrated that Udenafil is safe and effective for improving exercise capacity in Fontan palliative care patients who are at least 12 years old. The data provided by these trials are convincing and show meaningful clinical benefits for this orphan disease population, which lacks approved drug therapy options. Analysis of efficacy data in the Fontan subgroup that is most in need of treatment (those patients with less than normal exercise capacity, i.e., those with a baseline predicted peak VO2 percentage ≤ 80%) showed that the Udenafil drug effect observed in this subgroup is clearly clinically relevant. In addition, it is believed that the improvements observed in all important secondary measures of motor function, as well as improvements in myocardial performance indices as measured in the FUEL trial, constitute substantial evidence of the efficacy of Udenafil and support the clinical benefits of Udenafil therapy in the Fontan population (including super Fontan patients). This important clinical benefit and extremely low safety risk in the Fontan population demonstrate significant and unexpected results.
[0399] (2) References, each of which is incorporated herein by reference in its entirety:
[0400] Cordina R, du Plessis K, Tran D, d'Udekem Y. Super-Fontan: Is it possible? J Thorac Cardiovasc Surg. 2018;155(3):1192-4.
[0401] Cunningham JW,Nathan AS,Rhodes J,Shafer K,Landzberg MJ,OpotowskyAR.Decline in15peak oxygen consumption over time predicts death ortransplantation in adults with a Fontan circulation.Am Heart J.2017Jul;189:184-192.doi:10.1016 / j.ahj.2017.04.009.Epub 2017Apr 27.PMID:28625375.
[0402] Diller GP, Giardini A, Dimopoulos K, et al. Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients. Eur Heart J. 2010;31:3073 - 83.
[0403] Egbe AC, Driscoll DJ, Khan AR, Said SS, Akintoye E, Berganza FM, Connolly HM. Cardiopulmonary exercise test in adults with prior Fontan operation: The prognostic value of serial testing. Int J Cardiol. 2017 May 15;235:6 - 10. doi:10.1016 / j.ijcard.2017.02.140. Epub 25 2017 Feb 28. PMID:28284501.
[0404] Giardini A, Specchia S, Tacy TA et al. Usefulness of cardiopulmonary exercise to predict long - term prognosis in adults with repaired tetralogy of Fallot. Am J Cardiol 2007;99:1462 - 7.
[0405] Fernandes SM, Alexander ME, Graham DA, et al. Exercise testing identifies patients at increased risk for morbidity and mortality following Fontan surgery. Congenit Heart Dis. 302011;6(4):294 - 303.
[0406] Goldberg DJ, Zak V, McCrindle BW, et al. Exercise capacity and predictors of performance after Fontan: results from the Pediatric Heart Network Fontan 3 Study. Pediatr Cardiol. 2021;42(1):158 - 68.
[0407] McCrindle BW, Williams R, Mital S, et al. Physical Activity Levels in Children and Adolescents are Reduced After the Fontan Procedure, Independent of Exercise Capacity, and are Associated with Lower Perceived General Health. Arch Dis Child 2007;92:509 - 514. Doi:10.l136 / adc.2006.105239.
[0408] Navaratnam D, Fitzsimmons S, Grocott M, et al. Exercise-induced systemic venous hypertension in the Fontan circulation. Am J Cardiol. 2016;117(10):1667 - 71.
[0409] Ohuchi, H, Negishi, J, Noritake, K, et al. Prognostic Value of Exercise Variables in 335 Patients after the Fontan Operaton: A 23-year Single-center Experience of Cardiopulmonary Exercise Testing. Congenit Heart Dis. 2015;10:105 - 116.
[0410] Powell AW, Chin C, Alsaied T, et al. The unique clinical phenotype and exercise adaptation of Fontan patients with normal exercise capacity. Can J Cardiol. 2020;36(9):1499 - 507.
[0411] Scheffers LE, Berg L, Ismailova G, Dulfer K, Takkenberg J, Helbing W. Physical Exercise Training in Patients with a Fontan Circulation: A systematic review. Eur J Prev Cardiol 2020:0(0)1 - 12.
[0412] Tran DL, Gibson H, Maiorana AJ, et al. Exercise intolerance, benefits, and prescription for people living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F - FIT)-rationale and design. Front Pediatr. 2021;9:799125.
[0413] Udholm S, Aldweib N, Hjortdal VE, Veldtman GR. Prognostic power of cardiopulmonary exercise testing in Fontan patients: A systematic review. OpenHeart. 2018;5(1):e000812.
[0414] Weinreb SJ, Dodds KM, Burstein DS, et al. End-Organ function and exercise performance in patients with Fontan circulation: what characterizes the high performers? J Am Heart Assoc. 2020;9(24):e016850.
[0415] Each article, reference, patent document, and publication cited herein is hereby incorporated by reference in its entirety, as if fully set forth herein.
[0416] The present disclosure has been described with reference to example implementations. Modifications and changes will occur to others after reading and understanding the preceding detailed description. The present disclosure should be construed to include all such modifications and changes within the scope of the appended claims or their equivalents.
Claims
1. A method of treating a patient with univentricular heart disease (SVHD) having a single functioning normally functioning ventricle and Fontan physiology after a Fontan procedure (a Fontan patient) and in need of treatment to improve said Fontan patient's exercise capacity as measured by oxygen consumption at maximal effort or peak VO2, wherein said Fontan patient has a baseline peak or maximum VO2 that is less than (<) 80% of predicted, and wherein said Fontan patient's exercise capacity is adversely affected due to a decrease in cardiac function in said Fontan patient after said Fontan procedure, said method comprising: An effective amount of Udenafil or a pharmaceutically acceptable salt thereof is administered daily to the Fontan patient to improve the Fontan patient's exercise capacity as measured by oxygen consumption under maximum effort or peak VO2.
2. The method of claim 1, wherein the effective amount is a total daily dose of Udenafil or a pharmaceutically acceptable salt thereof in an amount between about 125 mg and 175 mg.
3. The method of claim 1, wherein the effective daily amount is a total daily dose of Udenafil or a pharmaceutically acceptable salt thereof in an amount of about 175 mg.
4. The method of claim 3, wherein the total daily dose consists of two separate doses of Udenafil or a pharmaceutically acceptable salt thereof, wherein each of the separate doses is about 87 mg of Udenafil or a pharmaceutically acceptable salt thereof.
5. The method of claim 4, wherein each of said individual doses is a solid oral dosage form.
6. The method according to claim 5, wherein the Udenafil or a pharmaceutically acceptable salt thereof is a solid or semisolid oral dosage form selected from tablets, capsules, gels, liquids, liquid dispersions, pills, powders and suspensions.
7. The method of claim 1, wherein the Udenafil or a pharmaceutically acceptable salt thereof is a solid oral dosage form.
8. The method of claim 7, wherein the solid oral dosage form is a solid or semisolid oral dosage form selected from the group consisting of tablets, capsules, gels, liquids, liquid dispersions, pills, powders, and suspensions.
9. The method of claim 1, wherein the Fontan patient is at least 12 years old.
10. The method of claim 1, wherein the method further improves the following motor performance of the Fontan patient: (a) ventricular performance of a single normally functioning ventricle in a Fontan patient as measured by the myocardial performance index (MPI); (b) exercise capacity as measured by oxygen consumption at the ventilatory anaerobic threshold (VAT); (c) performance under VAT; and (d) VE / VCO2 under VAT, either alone or in any combination.
11. A method of treating a patient with univentricular heart disease (SVHD) having a single functioning normal ventricle and Fontan physiology following a Fontan procedure (a super Fontan patient) and in need of treatment to improve said super Fontan patient's exercise capacity as measured by oxygen consumption at maximal effort or peak VO2, wherein said super Fontan patient has a baseline peak or maximum VO2 greater than or equal to (≥) 80% predicted, and wherein said super Fontan patient's exercise capacity is adversely affected due to a decrease in cardiac function in said super Fontan patient following said Fontan procedure, said method comprising: An effective amount of Udenafil or a pharmaceutically acceptable salt thereof is administered daily to the super-Fontan patient to improve the exercise capacity of the super-Fontan patient as measured by oxygen consumption at the ventilatory anaerobic threshold (VAT).
12. The method of claim 11, wherein the effective amount is a total daily dose of Udenafil or a pharmaceutically acceptable salt thereof in an amount between about 125 mg and 175 mg.
13. The method of claim 11, wherein the effective amount is a total daily dose of Udenafil or a pharmaceutically acceptable salt thereof in an amount of about 175 mg.
14. The method of claim 13, wherein the total daily dose consists of two separate doses of Udenafil or a pharmaceutically acceptable salt thereof, wherein each of the separate doses is about 87 mg of Udenafil or a pharmaceutically acceptable salt thereof.
15. The method of claim 14, wherein each of said individual doses is a solid oral dosage form.
16. The method of claim 15, wherein the Udenafil or a pharmaceutically acceptable salt thereof is a solid or semisolid oral dosage form selected from tablets, capsules, gels, liquids, liquid dispersions, pills, powders and suspensions.
17. The method of claim 11, wherein the Udenafil or a pharmaceutically acceptable salt thereof is a solid oral dosage form.
18. The method of claim 17, wherein the solid oral dosage form is a solid or semisolid oral dosage form selected from the group consisting of tablets, capsules, gels, liquids, liquid dispersions, pills, powders, and suspensions.
19. The method of claim 11, wherein the Super Fontan patient is at least 12 years old.
20. The method of claim 11, wherein the method further improves the following motor performance of the Super Fontan patient: (a) ventricular performance of a single functional normal ventricle of said Super Fontan patient as measured by the Myocardial Performance Index (MPI); (b) performance under VAT; and (c) VE / VCO2 under VAT, either individually or in any combination.
